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ABSTRACT 
Radiation is a common therapeutic modality for cancer however it fails to control advanced and 
malignant disease. As a result, novel approaches that aim to stimulate immune attack of tumors 
are currently being investigated and approved by the US FDA. It is clear, however, that no single 
agent will be responsible for achieving long-term control and treatment of cancer and that 
combination therapies will be required. Previous studies indicate that colorectal cancer cells that 
survive radiation up-regulate surface expression of cytotoxic T lymphocyte (CTL) relevant 
proteins including death receptors, cell adhesion molecules and tumor-associated antigens 
(TAA). The aim of this dissertation was to investigate the effect of non-cytolytic doses of 
ionizing radiation (IR) on co-stimulatory molecule expression on tumor cells and evaluate the 
impact of their modulation on effector T-cell biology and tumoricidal activity. Here, several 
human tumor cell lines were exposed to various doses of radiation (0-10Gy) and TAA-specific 
T-cell tumoricidal activity and expression of effector CTL co-stimulatory molecules were 
evaluated.  I found OX40L and 41BBL to be the most consistently upregulated proteins post-IR 
by flow cytometry.  Furthermore, I saw enhanced survival and activation of human CD8+ T-cells 
exposed to irradiated tumor cells. Importantly, enhanced killing of irradiated tumor cells by 
TAA-specific CTLs in cytotoxicity assays was reported.  Blocking OX40L and 41BBL reversed 
radiation-enhanced T-cell killing.  My data also indicate that expression of 41BBL and OX40L 
can be epigenetically regulated, as inhibition of histone deacetylases (HDAC) and of DNA 
methyltransferases (DNMT) resulted in increased OX40L and 41BBL mRNA and protein 
expression. Furthermore, chromatin immunoprecipitation experiments revealed increased histone 
H3 acetylation specifically at the 41BBL promoter following irradiation. Last, I began exploring 
the ability of IR to reverse immune suppression by evaluating the impact of radiation on 
regulatory T cells (TREGS) that can suppress the function of effector CTLs. I found that RT could 
reduce TREG numbers likely by altering their phenotype. Overall, this dissertation demonstrates 
that radiation can be used to make human tumors more immunogenic through epigenetic 
modulation of genes stimulatory to effector T-cells and that it may also reverse immune 
suppression by phenotypically altering TREG cells. 
 
 
INDEX WORDS: radiation therapy, cancer immunotherapy, ionizing irradiation, immunogenic 
modulation, CTLs, epigenetic, effector co- stimulation, and regulatory T cells. 
  
RADIATION EPIGENTICALLY MODULATES TUMOR CELLS AND ALTERS 
ACTIVATION AND FUNCTION OF EFFECTOR T CELLS 
 
 
 
by 
 
 
 
 
ANITA KUMARI 
 
 
 
 
 
A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
in the College of Arts and Sciences 
Georgia State University 
2015 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Anita Kumari 
2015  
RADIATION EPIGENTICALLY MODULATES TUMOR CELLS AND ALTERS 
ACTIVATION AND FUNCTION OF EFFECTOR T CELLS 
 
 
by 
 
 
 
ANITA KUMARI 
 
 
Committee Chair: Charlie Garnett-Benson 
 
Committee: Susanna F. Greer 
Andrew Gewirtz 
Zhi-Ren Liu 
Electronic Version Approved: 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
December 2015  
iv 
 
DEDICATION 
This dissertation is dedicated to my son Kush Kamal, and my husband Ram. This work 
would not have been possible without their perpetual love, faith, support, patience and 
encouragement.
v 
 
 
ACKNOWLEDGEMENTS 
I would like to express my deepest appreciation to my advisor, Dr. Charlie Benson for guiding, 
supporting and encouraging me throughout my PhD study. I would like to thank her for her 
unconditional availability and scientific inputs for every step in the research and providing an 
excellent laboratory atmosphere that is positive and very supportive, where an independent 
thought is encouraged but guidance is always available. Benson lab was an environment that 
allowed me to grow as a scientist and a person all while getting to work with a fantastic group of 
people. I would like to also thank my committee members Dr. Susanna F. Greer, Dr. Zhi-Ren 
Liu and Dr. Andrew Gewirtz for their valuable guidance and input through all the years of my 
research.  
vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................. v 
LIST OF FIGURES ....................................................................................................... viii 
LIST OF ABBREVIATIONS: ......................................................................................... x 
1 INTRODUCTION ...................................................................................................... 1 
1.1 Colorectal Cancer: .............................................................................................. 1 
1.2 RT enhances tumor immunogenicity ................................................................ 2 
1.3 Immunogenic modulation of tumor cells .......................................................... 2 
1.4 Cancer immunotherapies ................................................................................... 4 
1.5 Role of CD8 T cells: ............................................................................................. 6 
1.6 Immunosculpting and tumor immune escape: ................................................. 7 
1.7 Role of TREGS in cancer ....................................................................................... 9 
1.8 Current major gaps in our knowledge: ........................................................... 11 
2 Human colorectal carcinoma cells surviving radiation modulate expression of 
both OX40L and 41BBL, and promote CTL activation, survival and tumoricidal effector 
function. 15 
2.1 ABSTRACT: ...................................................................................................... 15 
2.2 INTRODUCTION:............................................................................................ 16 
2.3 MATERIALS AND METHODS: .................................................................... 20 
2.4 RESULTS ........................................................................................................... 24 
vii 
2.5 DISCUSSION .................................................................................................... 43 
3 Turning T cells on: Epigenetically enhanced expression of effector T cells 
costimulatory molecules on irradiated human tumor cells. .................................................... 49 
3.1 ABSTRACT: ...................................................................................................... 50 
3.2 INTRODUCTION:............................................................................................ 51 
3.3 METHODS: ....................................................................................................... 55 
3.4 RESULTS: ......................................................................................................... 59 
3.5 DISCUSSION: ................................................................................................... 76 
4 The impact of radiation directly on TREG viability and phenotype and indirectly 
via tumor modulation ................................................................................................................. 80 
4.1 ABSTRACT ....................................................................................................... 80 
4.2 INTRODUCTION ............................................................................................. 81 
4.3 MATERIALS AND METHODS ..................................................................... 82 
4.4 RESULTS ........................................................................................................... 85 
4.5 DISCUSSION: ................................................................................................... 93 
5 CONCLUSION: ........................................................................................................ 97 
REFERENCE ................................................................................................................ 108 
 
  
viii 
LIST OF FIGURES 
Figure 2.1: Sensitivity to CEA- and MUC-specific T-cell mediated cytolysis in 
irradiated colorectal tumor cells................................................................................................ 27 
Figure 2.2: T-cell activation is increased following exposure to irradiated colorectal 
tumor cells.................................................................................................................................... 30 
Figure 2.3: T-cell death is reduced following exposure to irradiated colorectal tumor 
cells. .............................................................................................................................................. 32 
Figure 2.4: Tumor cells modulate OX40L protein expression after treatment with 35 
Figure 2.5: Tumor cells modulate 41BBL protein expression after treatment with 
radiation. ...................................................................................................................................... 36 
Figure 2.6 Expression of CD70 and ICOSL following tumor cell irradiation. ......... 37 
Figure 2.7 Radiation-enhanced sensitivity to T-cell mediated lysis is reduced in the 
absence of OX40L and 41BBL. .................................................................................................. 40 
Figure 2.8: Radiation-enhanced sensitivity to T-cell mediated lysis and T-cell 
activation is reduced in the absence of OX40L and 41BBL. ................................................... 42 
Figure 3.1  5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA 
in HCT116 cells. .......................................................................................................................... 62 
Figure 3.2  5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA 
in SW620 cells. ............................................................................................................................. 65 
Figure 3.3 TSA and ionizing radiation increase surface expression of co-stimulatory 
molecules in SW620 cells more than 5AZA. ............................................................................. 68 
Figure 3.4 TSA and ionizing radiation treated HCT116 cells increase surface levels 
of 41BBL protein more than OX40L protein. .......................................................................... 69 
ix 
Figure 3.5 Histone acetylation at 41BBL promoters in non-radiated and irradiated 
cells. .............................................................................................................................................. 71 
Figure 3.6 : Enhanced survival of T-cells co-incubated with CRC tumor cells treated 
with TSA. ..................................................................................................................................... 72 
Figure 3.7 TSA-treated CRC tumor cells induce enhanced activation of CD8+ T-
cells. .............................................................................................................................................. 75 
Figure 4.1. The number of TREG cells following vivo RT of murine colorectal tumors.
....................................................................................................................................................... 86 
Figure 4.2. The number of FoxP3+ cells following vivo RT of murine breast tumors.
....................................................................................................................................................... 86 
Figure 4.3. Radiation induced changes in TREG promoting factors in human tumor 
cells. .............................................................................................................................................. 89 
Figure 4.4 The effects of irradiated tumor cells and direct RT on TREG and non-TREG 
cell viability. ................................................................................................................................. 91 
Figure 4.5.  Radiation directly modulates the phenotype of T-REG cells. ................... 93 
Figure 5.1 Immunogenic Modulation (IM) of Tumor Cells by IR. .......................... 100 
Figure 5.2  Diverse Mechanisms of Immunogenic Modulation (IM) Reported in 
Tumor Cells Surviving Radiation............................................................................................ 104 
 
 
 
 
 
x 
 
 
 
 
LIST OF ABBREVIATIONS: 
 
Radiation therapy (RT) 
Regulatory T cells (Tregs) 
Histone acetyltransferases (HATs) 
DNA methyl-transferase inhibitor (DNMTi) 
Cytotoxic T-cell (CTL) 
Trichostatin (TSA) 
5-Aza-2′-deoxycytidine (5Aza) 
HDAC inhibitors (HDACi) 
Adoptive T cell transfer (ACT) 
Major histocompatibility complex class I/II (MHC class I/II) 
Intercellular adhesion molecule-1 (ICAM-1) 
Cancer immunotherapy (CIT) 
Colorectal cancer (CRC) 
Immunogenic cells death (ICD) 
Dendritic cells (DC) 
Tumor associated antigens (TAAs) 
xi 
T cells receptor (TCR) 
Histone deacetylases (HDACs) 
DNA methyltransferases (DNMTs) 
Chromatin immunoprecipitation (ChIP) 
Ionizing radiation (IR) 
Carcinoembryonic antigen (CEA) 
Mucin-1 (MUC1) 
Antigen presenting cells (APC) 
Immunogenic modulation (IM) 
High mobility group box 1 (HMGB1) 
IFN g (interferon gamma) 
Monoclonal antibodies (mAbs) 
Programmed death-1 (PD-1) 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
Forkhead Box P3 (FoxP3) 
1 
1 INTRODUCTION  
1.1 Colorectal Cancer: 
Colorectal cancer (CRC) is the second leading cause of cancer related deaths in United 
States and the five-year survival rate is less than 30% for advanced colorectal cancer (Siegel, 
Desantis et al. 2014). According to the American Cancer Society more than 100,000 new cases 
of colorectal cancer, and around 50,000 deaths, are projected to occur in 2015. These numbers 
clearly demonstrate the urgent need to develop more efficient treatments and new therapeutic 
regimens for this disease. The standard therapies in advanced stage CRC include surgery, 
chemotherapy, targeted therapy, and radiation therapy (RT).  
RT is an integral part of cancer treatment and it is estimated that almost half of cancer 
patients undergo radiotherapy (RT) during the course of their illness (Schmid et al., 2012). In 
rectal cancer, RT is usually given either before or after surgery. In addition, radiation can be 
given in colorectal patients to palliate symptoms or to people who are not healthy enough for 
surgery. Radiation is delivered in three different ways to colorectal patients; these are external 
beam radiation (EBRT), brachytherapy and endocavitary (cancer.org). EBRT is commonly used 
in the clinic, in which the radiation source is kept outside the body to irradiate tumors. In 
contrast, brachytherapy employs the use of small pellets of radioactive material that are placed 
near or within the cancer tissue. Lastly, in endocavitary a small device is introduced, through the 
anus into the rectum that delivers high intensity radiation. Traditionally, radiation was thought to 
mediate its effect by direct killing of tumor cells. Accumulating evidence, however, indicates 
that radiotherapy triggers pro-immunogenic effects depending upon the dose of radiation, which 
include immunogenic cell death (ICD) and immunogenic modulation (IM)(Galluzzi, Maiuri et al. 
2007).   
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1.2 RT enhances tumor immunogenicity 
Immunogenic cells death (ICD) is defined as radiation-induced tumor cell death that 
results in release of specific signals, which enhance activation and cross presentation of tumor 
derived antigens by dendritic cells (DC) to T cells (Kroemer, Galluzzi et al. 2013). ICD induces 
three different molecular signals, which include: (1) the release of tumor associated antigens 
(TAAs), (2) the transport of calreticulin to cell surface, and (3) secretion of danger signals such 
as high mobility group box 1 (HMGB1), heat shock protein (HSP70), and ATP. First, novel 
TAAs (such as carcinoembryonic antigen (CEA) and mucin-1 (MUC1)) released from tumor 
cells exposed to lethal dose of irradiation are taken up, processed, and presented by DC 
(Hannani, Sistigu et al. 2011) to T cells. Second, calreticulin (a chaperone protein normally 
present in the lumen of ER) translocates to cell surface, which acts as a potent “eat me” signal to 
DCs facilitating phagocytosis of antigens. Third, the passive release of HMGB1 and HSP 70 
(Demaria et al., 2005; Tesniere et al., 2008) from dying tumor cells serves as danger signals that 
enhance DC activation via TLR receptor signaling. Moreover, tumor cell release of ATP 
following exposure to radiation activates the DC inflammasome, releasing IL-1β (a mediator of 
inflammatory response (Riteau, Baron et al. 2012). Overall, ICD is a distinct form of tumor cell 
death, inducing effective adaptive anti-tumor immune responses. 
 
1.3 Immunogenic modulation of tumor cells 
Apart from ICD, radiation causes immunogenic modulation (IM), which is defined as 
radiation-induced phenotypic changes on the tumor cell surface that can enhance cytolytic 
immune cell activity (Kwilas, Donahue et al. 2012, Wattenberg, Fahim et al. 2014). Radiation 
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increases expression of major histocompatibility complex class I and II (MHC class I/II;(Sanda, 
Restifo et al. 1995)), intracellular adhesion molecule-1 (ICAM-1;(Vereecque, Buffenoir et al. 
2000); (Garnett, Palena et al. 2004);(Reits, Hodge et al. 2006); (Ifeadi and Garnett-Benson 
2012)), co-stimulatory molecules (B7-1) and death receptors (Fas, DR4/DR5;(Ifeadi and Garnett-
Benson 2012)) on tumor cells. MHC class I is required for antigen presentation to T cells and 
B7-1 serve as a co-stimulatory signal to T cells (Lanier, O'Fallon et al. 1995). Furthermore, 
ICAM-1 binds to lymphocyte function-associated antigen (LFA3) and enhances the interaction 
between tumor cells and immune cells and subsequent cytolysis of target cells (ref). Importantly, 
radiation also increases expression of vascular cell adhesion molecule (VCAM-1;(Lugade, 
Moran et al. 2005)  and chemokine CXCL16 enhancing infiltration of T cells into the tumor 
(Matsumura, Wang et al. 2008). These findings support the ability of radiation to modulate the 
tumor milieu, inducing a better environment for immune attack. 
Despite these pro-immunogenic effects, radiotherapy alone fails to eradicate metastasis 
and to generate effective and long lasting T cell responses in patients. This outcome seems to be 
the result of multiple immunosuppressive strategies that have evolved in tumors, which reduce 
the optimal immune activities of radiotherapy in patients. Thus, additional interventions are 
required in conjunction with RT. Recently several studies have reported that RT enhances 
antitumor immune responses, particularly when combined with cancer immunotherapy (CIT) 
strategies, however the underlying mechanisms and optimal way to utilize RT specifically for 
this purpose are still unclear (Postow, Callahan et al. 2012, Golden, Demaria et al. 2013) 
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1.4 Cancer immunotherapies 
There are several advantages of CIT over standard therapies. Cancer immunotherapies 
offer the advantage of being systemic and rely on activating the host’s own immune response. 
Once activated, immune cells can effectively eliminate even microscopic lesions and 
disseminated metastasis (Dunn, Bruce et al. 2002). Moreover, memory cells can prevent the 
recurrence of cancer (Dimberu and Leonhardt 2011). Since both chemotherapy and radiation kill 
actively dividing cancerous cells; cancer stem cells, which usually stay in a quiescent state, are 
resistant to standard therapies (Moore and Lyle 2011). CITs involve the use of different 
strategies to enhance and stimulate antitumor immune responses, including monoclonal 
antibodies, therapeutic vaccination, and T cell transfer based immunotherapies (Dimberu and 
Leonhardt 2011). 
   Monoclonal antibodies (mAbs) can have been used therapeutically in diverse ways. In 
the last decade, the U.S. Food and Drug Administration (FDA) has approved a dozen of mAbs to 
treat both hematologic and solid malignancies (Scott, Wolchok et al. 2012). mAbs have less side 
effects than other immunotherapies; however, the rapid clearance from the body requires 
continued infusion of patients. Antagonist mAbs interfere with tumor cell signaling and tumor 
stroma interaction and can also cause antibody dependent cell mediated cytotoxicity of specific 
tumor targets. Antagonist mAbs are also currently being employed as “check-point blockers” to 
block inhibitory signals into responding T cells. Recently the US FDA has approved two such 
drugs, which block co-inhibitory receptors on activated T cells. Co-inhibitory receptors, such as 
cytotoxic T-lymphocyte-associated antigen-4 (CTLA4;(Hodi, O'Day et al. 2010)) and 
programmed death-1 (PD-1), control unwanted and harmful responses directed against self-
antigens, and play an important role in preventing autoimmunity (Sharpe, Wherry et al. 2007). 
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Within the tumor microenvironment they limit the generation of effective antitumor immune 
responses. Therefore, current approaches focus heavily on blocking these molecules CTLA-4 
and PD-1 to generate more effective antitumor response. Agonist mAbs can be used in used in a 
different manner from antagonist Abs to stimulated and promote positive signals into responding 
T cells.   Several preclinical studies are investigating how to combine radiotherapy with T cell 
inducing immunotherapy such as OX40 and 41BB agonist (Gough, Crittenden et al. 2010, 
Belcaid, Phallen et al. 2014) Varying degree of benefit have been achieved in phase I clinical 
trials using 41BB agonist abs. A trial was suspended due to hepatotoxicity associated at higher 
doses (Ascierto, Simeone et al. 2010). In addition, an antibody to human OX-40 antibody 
(MEDI6469) that targets an activating receptor on T cells (Curti, Kovacsovics-Bankowski et al. 
2013) is under study in a phase Iclinical trial study of 30 patients with advanced cancer. This 
study has reported some clinical activity in 12 out of 30 patients.  
Another commonly investigated CIT approach is vaccination, which employs the use of 
viral vectors, whole tumor cells, peptides, proteins or dendritic cells to elicit host immune 
responses to tumors (Chiang, Kandalaft et al. 2011). Sipuleucel-T/Provenge (dendritic cell based 
vaccine), for the treatment of metastatic castration-resistant prostate cancer was the first cell-
based immunotherapy to be approved by the FDA (Sims 2012). Therapeutic cancer vaccines, 
however, have limited success as compared to preventative vaccines, as tumors can actively 
suppress the immune system. To avoid tumor-mediated suppression of immune cells another 
immunotherapy, ,  Adoptive T Cell Transfer (ACT) therapy, involves removal of tumor 
infiltrating lymphocytes (TILs), expanding them ex vivo, and re-infusing them back into the 
patient  (June 2007, Rosenberg and Restifo 2015) . The major challenge with this personalized 
therapy is that it is labor intensive and very expensive. Moreover, infusion of T cells induces 
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severe cytokines storm and autoimmunity (Tey 2014). In spite of some of the negative side-
effects, immunotherapies are promising new strategies against cancer and complete responses 
have been reported (Acharya and Jeter 2013, Tan and Quintal 2015) and many of the side-effects 
can be medically managed. At present, however, CIT strategies used clinically seem to benefit 
only a minority of patients and it is unclear why they work so effectively in some and not others. 
Further, it seems clear that the most effective therapeutic responses have been observed when 
CITs were combined with standard therapies.  Thus, it seems likely that no single modality is 
sufficient to successfully eliminate and control advanced stage cancer. Moreover, most 
successful CIT strategies have been limited to melanoma and lung cancers. New combination 
approaches are needed to enhance the efficacy of CITs and expand its usage in other types of 
cancers apart from melanoma. In this regard, the diverse pro-immunogenic effects of RT can be 
exploited in combination with CIT.  In order to achieve the maximal synergistic effect, it is 
imperative to fully investigate and understand radiation-mediated cellular and molecular changes 
within tumors.  
 
1.5 Role of CD8 T cells:  
At the center of almost all CIT strategies is the desire to raise CD8+ cytotoxic T cells that 
recognize antigens expressed by transformed cells.  CD8+ T cell require two signals to become 
fully activated; the first signal involves recognition of peptides, displayed on MHC-I on antigen 
presenting cells (APC), by the T cell receptor (TCR) (Mueller, Jenkins et al. 1989). A second 
signal comes from the ligation of co-stimulatory molecules, B7-1/B7-2 on APC, with CD28 
receptors on naïve T-cells, this signal drives full activation of T cells prompting proliferation and 
IL-2 secretion (Driessens, Kline et al. 2009). In addition, other costimulatory molecules such as 
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ICOSL, CD70, OX-40L and 4-1BBL expressed by APC, engage cognate receptors on T cells 
and augments and amplifies expansion, differentiation and effector function of cytotoxic T cells 
(Kober, Leitner et al. 2008). Conversely, co-inhibitory molecules (CTLA-4 and PD-1) inhibit the 
effector activity of T cells. Therefore, to elicit an effective antitumor immune response, the 
immune system needs to recognize tumor antigens by TCR in conjunction with appropriate co-
stimulation (Kroczek, Mages et al. 2004, Jensen, Maston et al. 2010).  
Cytotoxic T cells are crucial in killing tumor cells with high specificity and efficiency 
(Finke, Rayman et al. 1990). CTLs kill target cells by one of the three distinct mechanisms. The 
first is mediated  when Fas ligand, which is expressed on CTLs, binds to its receptor (Fas/CD95) 
on target cells and triggers apoptosis by activating the caspase pathway (Nagata 1996). The 
second involves the use of perforin and granzyme. Perforin creates pores in the cell membrane 
and facilitates the entry of granzymes into the target cells and these lytic granules then lyse the 
target cells (Lowin, Peitsch et al. 1995). Lysis by granzymes can proceed through either a 
caspase dependent or caspase independent manner (Trapani and Smyth 2002). The third pathway 
involves the release of cytokines such as TNFα and IFNγ from CTLs (Ghanekar, Nomura et al. 
2001, Wohlleber, Kashkar et al. 2012). TNFα binds to its cognate receptor and triggers 
apoptosis. IFNγ induces MHC-I and Fas expression on target cells, thus enhancing antigen 
presentation of endogenous peptides and apoptosis, respectively (Andersen, Schrama et al. 
2006). 
 
1.6 Immunosculpting and tumor immune escape: 
Tumors employ multiple strategies to inhibit attack by immune cells and ultimately evade 
immune surveillance.   For example, tumors can decrease antigen presentation, down-regulate 
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co-stimulatory molecule expression, or recruit immunosuppressive cells into the tumor 
microenvironment (Marincola, Jaffee et al. 2000, Fujiwara, Higashi et al. 2004) , Liyanange et al 
2002). Decreased antigen presentation and processing can occur via several ways, such as loss of 
antigens, downregulation of TAP (transports degraded peptides into ER) and LMP2/7 unit 
(proteasome sub units that help in degradation of peptides), leading to reduced processing of 
antigen epitopes (Wang, Hu et al. 1993, Benitez, Godelaine et al. 1998). In addition, loss of β2 
microglobulin and heavy chain of MHC-I leads to diminished transport of MHC-I from ER 
through the golgi to the surface. Therefore, both processing and presentation of MHC-I is 
impaired in tumor cells, leading to tumor escape (Drake, Jaffee et al. 2006). Secondly, tumor 
cells can up-regulate co-inhibitory (PD-1, CTLA4) and down regulate co-stimulatory molecules 
(B7-1) (Fujiwara, Higashi et al. 2004). PD-1 is a co-inhibitory receptor on T cells and its ligand 
is PD-L1. Ligation of PD-1 promotes reduces TCR activation and induces apoptosis of CD8-T 
cells (Dong, Strome et al. 2002). Importantly, PD-L1 expression is increased in several tumors 
(Thompson, Gillett et al. 2004, Soliman, Khalil et al. 2014) and is correlated with poor prognosis 
(Thompson, Gillett et al. 2004).  In addition, secretion of soluble ligands such as MICA and 
MICB can also occur in some tumors and block lymphocyte activation (Groh, Wu et al. 2002).  
Consequently, because of weak immunogenicity (low expression of tumor associated antigens 
and MHC-I) and low expression of co-stimulatory molecules on tumor cells, CD8+ T cells 
undergo poor activation against many tumors (Demaria, Ng et al. 2004). 
Recruitment of immunosuppressive cells such as T-regulatory cells (TREG) and MDSCs 
into the tumor further suppresses the effector function of T cells (Jacobs, Nierkens et al. 2012, 
Lindau, Gielen et al. 2013). In addition to expression of PD-L1, MDSCs upregulate inducible 
nitric oxide synthase (iNOS), which metabolizes L-arginine, and produce nitric oxide (NO) that 
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induces apoptosis in activated T cells  (Saio, Radoja et al. 2001, Gabrilovich and Nagaraj 2009). 
Another important immunosuppressive cell type in tumor immunity is the CD4+ TREG (Baecher-
Allan, Brown et al. 2001, Brunkow, Jeffery et al. 2001). TREG infiltration is associated with poor 
prognosis and reduced survival in patients (Curiel, Coukos et al. 2004, Clarke, Betts et al. 2006). 
TREGS can inhibit killer T cell function by releasing suppressive cytokines (TGFβ and IL-10) 
or indirectly by inhibiting antigen presenting cells (Yamagiwa, Gray et al. 2001, Ghiringhelli, 
Puig et al. 2005, Schmidt, Oberle et al. 2012). 
 
1.7 Role of TREGS in cancer 
TREGS comprise 1-3% of total peripheral CD4+ T cells in humans and 5-10% of mouse 
splenocytes (Peng, Li et al. 2008).  CD4+ TREGS express high levels of CD25+ (interleukine-2 
receptor) and the forkhead box P3 (FOXP3) transcription factor; FOXP3 is regarded as a specific 
marker of TREGS as it controls transcription of several genes responsible for the suppressive 
function of TREGS (Baecher-Allan, Brown et al. 2001, Brunkow, Jeffery et al. 2001).  TREGS are 
important cells of the immune system as they inhibit and control unwanted immune responses 
against self-antigens, thereby protecting us from autoimmune diseases. On the other hand, TREGS 
inhibit the generation of anti-tumor T cell responses, thereby boosting cancer escape from 
immune-surveillance (Curiel 2007). In this regard, tumors can secrete different chemokine’s, 
which recruit TREGS into the tumor microenvironment (Wang 2006, Wolf, Rumpold et al. 2006). 
These recruited TREGS suppress the effector function of cytotoxic T cells present within tumor 
(Curiel 2007). 
     TREGS are comprised of natural TREGS (nTREGS) and induced TREGS (iTREGS), both 
subset of TREGS infiltrate into tumors (Baumgartner and McCarter 2009, Bour-Jordan and 
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Bluestone 2009). nTREGS are thymically derived, constitutively express FOXP3, and suppress 
effector T cells in a contact-dependent manner, using TRAIL (Ren, Ye et al. 2007) and/or  
perforin and granzyme (Gondek, Lu et al. 2005). In contrast, iTregs are generated in the 
periphery from naïve CD4+ T cells under tolerogenic cytokines condition and suppress effector 
CD8+ T cells without requiring contact by secreting suppressing cytokines such as IL-10 and 
TGF-β (Loser, Apelt et al. 2007, Strauss, Bergmann et al. 2007). Apart from direct inhibition, 
TREG suppress effector T cell by inhibition of dendritic cells activation. TREGS can increase 
indoleamine 2,3-dioxygenase (IDO) expression in DCs by CTLA4 signaling.  IDO is enzyme 
which degrades tryptophan to kynurenine. The depletion of tryptophan causes cell cycle arrest of 
T cells (Schmidt, Oberle et al. 2012) 
Increased numbers of TREGS has been found in different cancers; Woo and colleagues 
have reported increased number of intra-tumoral TREGS in lung and ovarian cancers (Clarke, 
Betts et al. 2006, Wolf, Rumpold et al. 2006). In particular, the ratio of CD8+ T cells to TREG cell 
infiltration in tumors is crucial in determining the prognosis (Curiel, Coukos et al. 2004). In a 
report by Ling and colleagues, both intra-tumor and systemic accumulation of TREGS has been 
reported in colorectal cancer patients (Ling, K.L., 2007). In addition, the proportion of TREGS in 
peripheral blood of CRC patients was four times higher than the control. Additionally, an 
increased frequency of TREGS was reported within tumor (19.2) as compared to normal colon 
tissue (9%) (Ling, Pratap et al. 2007). Overall, intra-tumoral infiltration of TREGS is a major 
obstacle to successful immune control of tumors. Based on these observations, depletion of 
TREGS has become an attractive approach to enhance antitumor responses (Jones, Dahm-Vicker et 
al. 2002, Li, Hu et al. 2003). 
   
11 
1.8 Current major gaps in our knowledge: 
I. The mechanisms contributing to enhance CTL activity in tumor cells surviving 
RT and the impact of irradiated tumor cells on CTL biology.  
 IR has the ability to modulate gene expression in tumor cells in ways that make them 
better stimulators of immune cell function (Wattenberg, Fahim et al. 2014). Garnett el al have 
reported that sub-lethal irradiation of colorectal carcinoma cells (CRC) lines results in enhanced 
lysis by tumor specific CTLs following 10Gy of irradiation (Garnett, Palena et al. 2004). 
Moreover, CTL killing was MHC restricted as LS174 cells which lack HLA-A2 are not killed by 
these HLA-A2-restricted CTLs. Other studies have also reported enhanced killing post RT  
against head neck squamous carcinoma (Gelbard, Garnett et al. 2006) and prostate carcinoma 
cells (Chakraborty, Wansley et al. 2008). Previous studies from our lab reveal that SW620 cells 
are effectively killed by CTL after RT. Though these cells significantly increase expression of 
the death receptor Fas, this pathway is non-functional in these cells (Ifeadi and Garnett-Benson 
2012). Moreover, the increased lysis by CTLs does not obviously correlate with either enhanced 
expression of MHC-I, nor expression of the tumor antigens CEA or MUC-1. Thus one part of 
this study was designed to investigate the underlying mechanisms of enhanced killing of 
irradiated tumor by CTLs.  Moreover, while enhanced killing by CTLs has been reported, no 
other aspects of T cell biology have been reported following interaction with irradiated tumor 
cells.  
 
II. How RT modulates gene expression in cells receiving sub-lethal doses:  
     Previous studies demonstrate that sub-lethal doses of radiation alter the expression of 
immune relevant genes within tumor cells making tumor cells more susceptible to cytotoxic T-
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cell (CTL) mediated lysis (Garnett, Palena et al. 2004). Several mechanisms have been described 
for how IR can modulate expression of immune relevant genes in tumor cells. While LD-RT 
(<2Gy) has been shown to reduce NF-κB via proteasome inhibition, hypofractionated doses of 
IR (2-25Gy) have conversely demonstrated increased activity of NF-κB.  NF-κB can be activated 
in different cell types within an irradiated tumor mass including the tumor cells, stromal cells, 
cells of the vasculature, and immune cells. In tumor cells, genotoxic stress induced NF-kB 
activation is initiated by DNA double strand breaks (DSB) in the nucleus and can stimulate gene 
expression. NF-κB activation has been reported to occur in this manner in diverse tumor cell 
lines in an ataxia telangiectasia mutated (ATM) dependent pathway, mostly at doses above 3Gy.  
ATM signaling is also a well-known activator of p53. p53 target genes, however, are related 
mostly to cell cycle, apoptosis and DNA repair pathways (reviewed in (Criswell, Leskov et al. 
2003)). While most p53 inducible genes are not typical immune relevant genes, apoptosis 
inducing death receptors could be important for immune cell mediated signals transmitted from 
death ligands on cytotoxic immune cell. Unfortunately, less than 50% of tumor cells retain 
functional p53. 
   Epigenetic changes play an important role in regulating the expression of many genes 
through histone modifications and DNA methylation, and radiation has recently been reported to 
influence these pathways, For example, radiation has been shown to inhibit the expression of 
histone deacetylase 1 (HDAC1) and HDAC2 [37].HDAC enzymes remove acetyl groups from 
histones and often inhibit transcription of genes [Kadosh D; Wang Z; Glozak MA]. In several 
tumors, HDACs are up regulated (Ropero S, 2007 Mol Oncol 1(1): 19–25; Sharma N, 2010 Br J 
Urol Int; in press)[Barneda-Zahonero B 2012, Marks P 2001]. Recent studies have shown that 
HDAC inhibition can have immune-modulatory properties, such as increasing expression of 
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HLA-DR, ICAM-1 and B7-2 in cancer cell lines (Takahiro Maeda, blood 2013).  HDAC 
inhibitors (HDACi) have been shown to induce a potent antitumor response (Saunders N, Cancer 
Res. 1999; 59:399-404, Redner RL, Blood. 1999; 94:417-428).   
 DNA methylation also plays an important role in regulation of genes (Razin A, 1991) 
and IR has recently been reported to induce DNA hypomethylation and alter gene expression in 
CRC cells treated with 2-5Gy (Bae, Kim et al. 2015)..  DNA methyl transferase enzyme 
(DNMT1) adds a methyl group to cytosine residue and causes silencing of genes (Gal-Yam EN 
2008). DNA hyper-methylation occurs at CpG islands and more than half of human promoter 
genes contain CpG islands (Yam, G., Annu. Rev. Med. 2008. 59:267–80). Aberrant methylation 
is found in colorectal cancer such as hyper methylation of mismatch repair gene (hMLH1) 
(Chiam, K. PLoS ONE September, 2011). In addition, promoter hyper-methylation and genome-
wide hypo methylation alters genes expression in colorectal cancer (Cheng, Y.W., Clin Cancer 
Res 2008; 14:6005-6013). 5-Aza-2′-deoxycytidine (5Aza) is a DNA methyl-transferase inhibitor 
(DNMTi) that is incorporated into DNA and leads to rapid loss of DNA methyl transferase 
activity (Kane MF, Loda M, Gaida GM, et al. 1997). 5Aza has been reported to alter the 
expression of other immune relevant genes, such as MHC I, MHCII, CD80, CD86 and CD40 on 
chronic lymphocytic leukemia cells has also been reported (Dubovsky, J.A., Clin Cancer Res 
2009; 15:3406-3415). However, it is remains unclear if radiation modulates expression of 
immune-relevant genes via epigenetic mechanisms. This could be important for combination 
radiation-immunotherapy approaches, as epigenetic changes can be maintained for quite some 
time within the cell population. Thus, a major gap in our knowledge is how radiation 
modulates expression of immune relevant genes in tumor cells that survive radiation 
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III. The impact of RT on CD4+ TREG cells versus CD4+ non-TREG cells  
   Relatively few and contradictory data exist in the literature regarding the effect of 
irradiation on TREGS and there are many gaps in our knowledge about the impact of RT directly 
on TREGS. The absolute number and frequency of TREGS was reported to be decreased in naïve 
mice receiving low dose total body irradiation (Liu, Xiong et al. 2010). However, studies by 
others suggest that regulatory T cells are more resistant to radiation than non-TREGS (Billiard, 
Buard et al. 2011, Balogh, Persa et al. 2013). Thus it is not clear how hypofractionated doses of 
IR (2-10Gy) directly impact human TREGS. Further, it is unclear if sub-lethal irradiation of tumors 
can indirectly impact human TREG number and function through modulation of tumor cells as 
these reports were made in non-tumor bearing mice. For example, do irradiated tumor cells 
secrete cytokines or chemokine’s that could decrease conversation and/or recruitment of TREGS 
within tumors? Do irradiated tumor cells modulate the expression of ligands that can alter the 
biology of TREGS and repress TREG suppressive function? 
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2 Human colorectal carcinoma cells surviving radiation modulate expression of both 
OX40L and 41BBL, and promote CTL activation, survival and tumoricidal effector 
function.  
 
2.1 ABSTRACT: 
Sub-lethal doses of ionizing radiation (IR) can alter the phenotype of target tissue by 
modulating genes that make tumor cells more susceptible to T-cell–mediated immune attack.  
Previous studies indicate that colorectal cancer cells responded to radiation by up-regulating 
surface expression of CTL relevant proteins including death receptors, cell adhesion molecules 
and tumor-associated antigens (TAA).  The aim of this study is to investigate the effect of 
noncytolytic doses of ionizing radiation on co-stimulatory molecule expression on tumor cells 
andthe impact of their modulation on effector T-cell biology and tumoricidal activity. Here, 
several human tumor cell lines were exposed to various doses of radiation (0-10Gy) and TAA-
specific T-cell tumoricidal activity and changes in the expression of effector CTL co-stimulatory 
molecules were evaluated. One to seven days post-IR, changes in expression of OX40L and 
41BBL, as well as expression of other molecules stimulatory to effector T-cell activity (ICOSL 
and CD70), was examined by flow cytometry. We found OX40L and 41BBL to be the most 
consistently upregulated proteins post-IR, and increased transcripts for both genes were detected 
24 and 48hr post-IR by quantitative RT-PCR.   Furthermore, we saw enhanced survival and 
activation of human CD8+ T-cells exposed to irradiated tumor cells. Importantly, expression of 
these gene products correlated with enhanced killing of irradiated tumor cells by TAA-specific 
CTLs in cytotoxicity assays.  Blocking OX40L and 41BBL reversed radiation-enhanced T-cell 
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killing of tumor targets as well as T-cell activation.  Overall, results of this study suggest that 
human tumor cells surviving radiation are more amenable to immune attack by modulating 
expression of molecules that are co-stimulatory to effector T cells.  
 
2.2 INTRODUCTION: 
   In addition to surgery and chemotherapy, radiotherapy (RT) is a common modality in 
cancer treatment.  Many cancer patients undergo RT during their course of illness, but as a 
definitive therapy RT can fail to control local tumor growth as tumor cells acquire mutations 
during development that inhibit cell death by radiation (Baskar, Lee et al. 2012).  RT also fails to 
control systemic disease, such as undetectable metastasis, and many cancer patients experience 
disease recurrence and death (Hodge, Guha et al. 2008).  Moreover, radiation kills both 
malignant cells and non-malignant cells, resulting in significant dose limiting toxicities when 
used as a single agent (Yeoh 2008, Kumar, Juresic et al. 2010). It has becoming increasingly 
clear that no single modality will be effective against advanced stage cancers.  Cancer 
immunotherapy (CIT) is emerging as an attractive therapeutic option and many standard cancer 
therapies, such as chemotherapy and radiation, rely on induction of functional immune cells for 
efficacy (Demaria, Kawashima et al. 2005, Zitvogel, Apetoh et al. 2008).   Indeed, combination 
CIT and RT is more effective in treating metastatic and reoccurring cancers than either of the 
therapies alone (Hillman, Xu et al. 2003, Chakraborty, Abrams et al. 2004, Chi, Liu et al. 2005, 
Kaufman and Divgi 2005, Newcomb, Demaria et al. 2006, Yokouchi, Chamoto et al. 2007, 
Lechleider, Arlen et al. 2008, Ferrara, Hodge et al. 2009, Gough, Crittenden et al. 2010).  
Disappointingly, synergy has yet to be achieved in many combination CIT and RT clinical 
studies.  The reasons for this unexpected lack of clinical response have yet to be resolved and the 
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relevant molecular details of combining RT with CIT are just beginning to be revealed.  Fully 
understanding the role of RT in tumor immunity will have a major impact on the treatment of 
cancers combining these modalities.  
   It is well established that the most effective cancer immunotherapy (CIT) strategies 
generate tumor-associated antigen (TAA)-specific CD8+ CTLs capable of killing tumor cells 
(Blattman and Greenberg 2004, Dunn, Old et al. 2004). To elicit an effective immune response 
against tumors, the immune system needs to recognize TAA presented to the TCR within MHC 
Class-I molecules, in conjunction with appropriate co-stimulation (Kroczek, Mages et al. 2004, 
Jensen, Maston et al. 2010).  Interestingly, anti-tumor immune cells can be detected in most 
cancer patients, and therapies that further induce large numbers of anti-tumor CTLs do not 
consistently translate into objective clinical tumor responses.  Several possibilities for this 
include weak immunogenicity of TAA, low expression of co-stimulatory molecules on tumor 
cells and APCs, and/or secretion of suppressive molecules or cells. Thus, it takes more than 
increasing tumor-specific CTL numbers to control malignant cells and eliminate cancer.   
 Local tumor irradiation has been shown to generate tumor-specific CTL and enhance 
anti-tumor immune responses (Friedman 2002, Chakraborty, Abrams et al. 2003, Chakravarty, 
Guha et al. 2006, Formenti and Demaria 2008, Takeshima, Chamoto et al. 2010). Sub-lethal 
doses of ionizing radiation (IR), for example, have been reported to up-regulate expression of 
immune-stimulatory proteins in various tissue types both in vitro and in vivo (Friedman 2002, 
Garnett, Palena et al. 2004).  We previously reported that exposure of human carcinoma cell 
lines to sub-lethal radiation results in enhanced susceptibility to lysis by tumor specific cytotoxic 
T cells (CTLs) (Garnett, Palena et al. 2004, Gelbard, Garnett et al. 2006).  Significantly 
enhanced killing by CEA-specific CD8+ CTLs was observed in five of five colorectal carcinoma 
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(CRC) cell lines exposed to a single dose of 10Gy radiation. T-cell killing was MHC-restricted, 
as irradiated CEA+/HLA-A2- colon cells were not killed.  Furthermore, enhanced attack by CTLs 
in head and neck squamous cell carcinoma (Gelbard, Garnett et al. 2006) and prostate carcinoma 
(Chakraborty, Wansley et al. 2008) suggests the functional enhancement is not limited to a single 
antigen-specificity or cancer type.  More recently we reported that irradiation of human tumor 
cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways 
(Ifeadi and Garnett-Benson 2012); however, the differences in magnitude of lysis among the cell 
lines does not correlate with altered expression of death receptors, nor altered surface expression 
of MHC-I, ICAM-1 or TAAs (Garnett, Palena et al. 2004).  Thus, the mechanism of enhanced 
CTL killing against human carcinoma cells is unclear and surprisingly few studies focus on 
understanding the effect of radiation-induced changes in tumor cells on CTL effector activity.    
  As self-antigens, tumor derived antigens often induce insufficient co-stimulation, 
resulting in tolerance. Antigen presentation in a toleragenic or immunosuppressive environment 
where robust costimulation is not present leads to sub-optimal immune responses such as T-cell 
anergy.  T-cell co-stimulatory agonists can program T cells encountering these non-
immunogenic antigens to expand and develop anti-tumor effector activities (Adler and Vella 
2013).  As a result, strategies for improving positive co-stimulation and reversing negative 
regulation are currently very attractive therapeutic approaches for cancer therapy.  In this regard, 
the co-stimulatory TNFSF members 41BB ligand (41BBL/TNFSF9/CD137L) and OX40 ligand 
(OX40L/TNFSF4/CD134L/CD252) represent important regulators of effector CTL activity, and 
lack of signaling through these molecules results in sub-optimal CTL activity (Kroczek, Mages 
et al. 2004, Watts 2005, Mescher, Curtsinger et al. 2006, Kober, Leitner et al. 2008). In tumor 
bearing mice, intratumoral OX40 activation increases CD40 expression on T cells and increases 
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the effector memory T cells (TEM) subset (Burocchi, Pittoni et al. 2011).  41BBL 
(TNFRSF9/CD137) costimulation of tumor-specific T cells is important for T-cell proliferation, 
cytokine production and activation. 41BBL transfected DCs elicit more effective responses and 
enhanced CTL killing of tumor cells, due to increased expression of perforin and IFN-γ (Song, 
Guo et al. 2012).  In recognition of the importance of these pathways to generating effective 
antitumor immunity, clinical studies have started to evaluate the effectiveness of humanized 
agonist antibodies to both OX40 and 41BB (Ascierto, Simeone et al. 2010, Garber 2011, Kohrt, 
Houot et al. 2011, Weinberg, Morris et al. 2011). Engagement of OX40 and 41BB by agonist 
(activating) antibodies increases tumor immunity, resulting in long-term survival in a number of 
murine tumor models (Melero, Shuford et al. 1997, Lee, Myers et al. 2004, Watts 2005, Murata, 
Ladle et al. 2006). These costimulatory signals may be particularly important for effective 
responses against self-antigen such as those expressed by many tumor cells.  In the absence of 
these costimulatory signals anti-tumor effector T-cells may be rendered anergic. 
      Our previous studies suggest that sub-lethal doses of radiation cause altered 
expression of genes within tumor cells, making tumor cells more susceptible to CTL-mediated 
lysis (Garnett, Palena et al. 2004).  Subsequently, we have found that radiation-enhanced CTL 
killing of tumor cells is independent of death receptor pathways (Ifeadi and Garnett-Benson 
2012).  The present study was designed to test the hypothesis that enhanced killing of human 
colorectal carcinoma cells by CTLs is due to prolonged survival and activation of CD8 T cells 
that is imparted by increased expression of co-stimulatory molecules on tumor cells after 
radiation treatment.  To our knowledge, this is the first study to a) demonstrate that doses as low 
as 5Gy can enhance lysis of human CRC tumor cells by CTL of diverse antigen specificity, b) 
show that T cells co-cultured with irradiated CRC cells have increased expression of activation 
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markers and enhanced survival as compared to T cells cultured with non-irradiated tumor cells,  
c) measure the expression of several effector CTL co-stimulatory molecules including OX40L, 
41BBL, CD70 and ICOSL on human tumor cells and find OX40L and 41BBL expression 
upregulated in five of six CRC tumor cell lines post-IR, d) find that CTL killing of irradiated 
tumor cells was abolished in the presence of a neutralizing antibody against OX40L and silenced 
41BBL expression.  Overall, the results of this study suggest that sub-lethal doses of radiation 
can be used to make human tumors more amenable to immune attack, even in the absence of 
innate immune responses to “danger” from dying cells.  
 
2.3 MATERIALS AND METHODS: 
Cell lines: Human colorectal carcinoma cell lines HCT116, Caco-2 and WiDr were 
obtained from the laboratory of tumor immunology and biology, LTIB, NCI, NIH. HT-29, 
LS174T and Colo205 cells were purchased from ATCC. The cell line SW620 was kindly 
provided by Zhi-Ren Liu from Georgia State University, Department of Biology. All cells were 
cultured as recommended by ATCC and tested periodically to ensure absence of Mycoplasma. 
Cells were incubated at 37°C incubator with 5% CO2.  
Irradiation: A RS-2000 biological X-ray irradiator (Rad source technology, Suwanee, 
GA) was used to irradiate tumor cells. Cells were irradiated at a dose rate of 2Gy/min at voltage 
and current of 160kV and 25mA, respectively. Cells were maintained in suspension and kept on 
ice during irradiation. Immediately after irradiation, cells were centrifuged and cells were plated 
in tissue culture plates in fresh media.  
RNA isolation: At 24 or 48hr post-IR, RNA was extracted from tumor cells using 
RNeasy mini kit (Qiagen Inc. Valencia, CA) according to manufacturer’s instructions.  Purified 
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RNA was DNase-treated by Rnase-free DNase (Qiagen Inc. Valencia, CA) following 
manufacturer’s instructions. 
Quantitative real time PCR: Expression of OX40L and 41BBL mRNA was determined 
using real time qRT-PCR. cDNA was synthesized using 500ng of mRNA. Amplification of 
cDNA was done using DyNaAmo cDNA synthesis kit (Finnzymes. Vantaa, Finland). 
Quantitative RT-PCR was conducted using TaqMan gene expression assay (Applied Biosystems; 
OX40L; Hs00967195, 41BBL; Hs00169409, and HPRT; Hs99999909) according to 
manufacturer’s protocol. PCR thermal cycling condition was 50°C for 2min, 95°C for 10min, 40 
cycles of 95°C for 15sec and 60°C for 1min in a total volume of 20 μl/reaction. Data were 
collected using a 7500 Real Time PCR System. All samples were run in duplicate. The 
expression level of each gene was compared between irradiated and non-irradiated samples 24 or 
48hr post-IR.  Hypoxanthine phosphoribosyltransferase (HPRT) was used as an endogenous 
house-keeping control gene and samples were normalized to expression of this gene, which was 
unchanged by radiation.  Data were analyzed using the comparative ΔΔCt method (Livak and 
Schmittgen 2001). 
Flow cytometry: Cells were stained with primary labeled mAb [CD137L (41BBL)-PE, 
CD252 (OX40L)-PE, CD70-FITC, ICOSL-PE, CD8α-FITC, CD25-APC, CD69-PE, CD66-PE, 
CD227 (MUC-1)-FITC] purchased from BioLegend or BD biosciences (San Diego, CA).  
Surface staining was done in cell staining buffer for 30min on ice. Annexin-V-PE and 7AAD dye 
were obtained from BD biosciences (San Diego, CA) and used according to manufacturers 
instructions to measure cell death. Intracellular staining of active caspase-3 was done according 
to manufacturer’s instruction. Flow cytometry data were acquired on BD Fortessa and analyzed 
with FlowJo software (TreeStar, version 9.6).  The live cells population was gated on the FSC 
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and SSC scatter plots for analysis of surface proteins.  No live cells gate was used for cell death 
analysis samples.  Samples were stained with the appropriate isotype control antibodies and gates 
were set to less than 5% in all isotype control samples.  Expression was considered increased if 
the absolute percent positive population increased by 10% or greater. 
T-cell activation and survival assay: 1 × 103 colorectal tumor cells were irradiated with 
5, 10, or 15Gy and plated in 96-well plate for 48hr. 1×104 human CEA specific CD8+ T cells 
were subsequently added and co-cultured with the irradiated colorectal tumor cells for 24-48hr.  
The percent of T cells expressing CD69 or CD25 was measured by flow-cytometry.  In parallel 
experiments, Annexin-V and 7AAD were used to measure T-cell death.  Cell stimulation 
cocktail (1X) of PMA and ionomycin (eBioscience) was used as a positive control for activation 
of TAA-specific T-cells.  In some experiments, activation of CTLs was determined after 
additional co-incubation of T-cells and tumor cells for 48h (beyond the 4h cytotoxicity assay). 
Generation TAA-specific cytotoxic T-lymphocytes: PBMCs from HLA-A2+ donors 
were purchased from Hemacare (Van Nuys, CA) for the generation of antigen specific CTLs as 
described elsewhere (Tsang, Zaremba et al. 1995, Tsang, Zhu et al. 1997, Gelbard, Garnett et al. 
2006). Briefly, PMBCs were allowed to adhere to T150 flask for 2hr in AIM-V media. After 2hr, 
non-adherent cells were removed for lymphocyte isolation. Adherent cells were cultured for 
seven days in the presence of 100ng/ml of human granulocyte colony stimulating factor (GM-
CSF) and 20ng/ml of IL-4 (Miltenyi Biotec, Inc. Auburn, CA) in AIM-V media and 500ng/ml 
CD40L (Millipore corporation, Temecula, CA) was added on day five to mature the DCs. On 
day seven DCs were collected and pulsed with 40μg/mL of HLA-A2 binding CEA peptide 
(YLSGANLNL (CAP-1; (Tsang, Zhu et al. 1997)), 40μg/mL of MUC (ALWGQDVTSV) or 
peptide or 40μg/mL of Melan-A/MART-1 (AAGIGILTV) peptide (Rivoltini, Barracchini et al. 
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1995) for 4hr in a 37°C 5% CO2 incubator.   Unused DCs were frozen and stored in liquid 
nitrogen for subsequent resitmulations.  DCs loaded with peptide were subsequently irradiated 
with 50Gy. Immunomagnetic beads (Miltenyi Biotec Inc. Auburn, CA) were used to isolate 
CD8+ T cells from the non-adherent cells, following manufacturer instructions. Subsequently, 
isolated CD8+ T cells were co-cultured with peptide pulsed DCs. IL-7 (Millipore, Temecula, 
CA) at 10ng/ml and IL2 (Millipore, Temecula, CA) at 30U/ml were added to each well on the 
first and third day, respectively.  T-cells were restimulated in this manner weekly using mature 
autologous DCs.  Restimulated T cells were isolated over ficoll on day four or five of culture, 
and used in a standard cytotoxic killing assay.   
Cytotoxicity assay: CTL lysis of HCT116, SW620, Colo205 (HLA-A2+) and LS174T 
(HLA-A2-) tumor cells was measured using the DELFIA cell cytotoxicity kit (Perkin Elmer).  
72hr after irradiation, viable and proliferating tumor cells (2x106/2ml) were incubated with 5μl 
of BATDA (bis (acetoxymethyl) 2,2':6',2''- terpyridine- 6,6''- dicarboxylate; PerkinElmer, 
Boston, MA) for 20min at 37°C. After incubation, cells were washed four times with PBS.  
5x103 cells were added in triplicate to a 96-well U-bottom plate, and either CEA or MUC 
specific CD8+ T-cell were added to the wells (E:T ratios between 10:1 and 30:1) and incubated 
for 4-5hr at 37°C. After incubation, the plate was centrifuged (500Xg for 5min) and 20μl of 
supernatant were transferred into a flat bottom plate. 200μl of Europium solution was added and 
incubated for 15min at room temperature on plate shaker (Bohlen, Manzke et al. 1994).  Lysis 
was measured on a time resolved Victor3 plate reader fluorometer. The percentage of tumor lysis 
was calculated as follows: % tumor lysis=experimental release (counts) -spontaneous release 
(counts))/ maximum release (counts)- spontaneous release (counts) x 100.  T-cells stimulated 
using Melan-A peptide were used as a control for T-cell antigen specificity.  
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Expression knockdown and blocking: 41BBL gene expression was knocked down 
using a gene specific siRNA.  Briefly, tumor cells were plated in a 6-well dish at 1x 105 
cells/well one day prior to transfection, with 50-70% confluence on the day of transfection.  In 
some experiments 2 x 104   cells were plated in 24-well plates.  41BBL Flexi Tube siRNA 
(Qiagen Inc. Valencia, CA) was diluted in optiMEM medium (Invitrogen) and transfected using 
Hyperfect (Qiagen Inc. Valencia, CA). Twenty-four hours post transfection; cells were irradiated 
with 10Gy or mock-irradiated. The cells were harvested 24 to 48hr post irradiation and 41BBL 
mRNA expression was measured.  A negative control siRNA that was not specific to 41BBL was 
also transfected into cells and 41BBL mRNA similarly evaluated.  To block OX40L activity, we 
used a Goat anti-human OX40L-neutralizing antibody (R&D system, Minneapolis, MN) to block 
OX40 ligand and receptor interaction (cat #: AF1054).  In the indicated groups, 500ng/ml of 
anti-human OX40L neutralizing antibody was added to Eu-labeled tumor cells for 15min prior to 
adding TAA-specific CTLs. The anti–human 41BB monoclonal blocking antibody BBK-2 (Lee, 
Park et al. 2002) was added 20μg/ml 15min before T-cells were added.  Isotype matched 
antibodies were added to the other groups as a negative control.  
Statistical Analysis: For graphed flow cytometry data, the mean of three to four 
independent experiments were calculated and an un-paired one-tailed student T-test was 
performed using Graphpad by Prism.  Statistical differences between groups in the cytolysis 
assays were calculated using un-paired two-tailed student T-test.  
2.4 RESULTS 
Sub-lethal irradiation increases CEA and MUC-specific cytotoxic T-cell mediated 
killing of HCT116 and SW620 cells, but not of Colo205 cells. 
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     We previously demonstrated that treatment of tumor cells with 10Gy of radiation enhanced 
tumor cell sensitivity to carcinoembryonic antigen (CEA) specific CTL mediated killing in an 
18hr cytolysis assay (Garnett, Palena et al. 2004).  We wanted to further evaluate if this 
enhanced killing occurred if a lower dose of radiation was used.  Human colorectal tumor cell 
lines HCT116, SW620 and Colo205 were irradiated with a single dose of 0, 5 or 10Gy radiation.   
Following tumor cell irradiation only adherent and proliferating cells were harvested. We have 
previously demonstrated that tumor cells remain viable and continue to proliferate using this 
method (Ifeadi and Garnett-Benson 2012).  At 72hr post-IR, tumor cells were evaluated in a 4hr 
Europium-release cell cytotoxicity assay (Bohlen, Manzke et al. 1994) with CEA-specific CTLs.   
Similar to our previous observations, 10Gy irradiated SW620 and HCT116 tumor cells were 
killed significantly better by CEA-specific CTLs when compared to non-irradiated tumor cells 
(Fig. 2.1A).   Tumor cell lysis by CTLs could also be observed in tumor cells receiving as low as 
5Gy of radiation (17.9% lysis of SW620 and 5% lysis of HCT116). We also wanted to evaluate 
if CTL that were specific to another TAA expressed in these colorectal tumor cells would 
demonstrate enhanced killing of irradiated tumor targets.   For this, tumor cells were evaluated 
72hr post-IR in a cytotoxicity assay using mucin-1 (MUC1) specific cytotoxic T cells.  MUC-
specific CTLs did not lyse non-irradiated SW620 cells, however lysis increased to 32.7% and 
44.1% if tumor cells received 5Gy (P=0.0278) or 10Gy (P=0.0013) of radiation, respectively 
(Fig. 2.1B).  Here, both HCT116 cells and SW620 tumor cells displayed significantly enhanced 
killing by MUC specific CTLs after irradiation with 10Gy (p=0.015 HCT116), and again killing 
could be observed when 5Gy of radiation was used.  Thus, these data suggest that tumor cells 
surviving irradiation are more susceptible to cytotoxic T-cell killing by T cells of diverse antigen 
specificity and at doses lower than the previously reported 10Gy.  In contrast to the killing of 
26 
SW620 and HCT116 tumor cells, the percent lysis by both CEA-specific and MUC-specific T-
cells was below 10% after irradiation of Colo205 cells and untreated cells were also not killed 
(Fig. 2.1C). Furthermore, Lysis of MHC-mismatched colorectal tumor cells LS174T 
(CEA+MUC+/HLA-A2-) was less than 5% at all doses of radiation in the same assay even 
though both CEA and MUC expression was increased (Fig. 2.1D).  
     It is unclear what causes the variable magnitude of cytolysis among the cell lines examined, 
however these differences do not appear to correlate with altered surface expression patterns of 
MHC-I, or TAA.  Specifically, HCT116 cells are killed post-IR while Colo205 cells are not (Fig. 
2.1A & 2.1C).  This occurs despite the fact that Colo205 cells express more MHC molecules per 
cell than HCT116 cells, as determined by both mean fluorescence intensity (MFI) (255 vs 226 
respectively) and percent positive cells (74.6% vs 99.5%) (Fig.2.1E). SW620 and HCT116 cells 
demonstrate similarly enhanced cytolysis by CEA-specific CTLs post-IR (Fig. 2.1A).  SW620 
cells express more MHC-I (MFI 302) than HCT116, however, they actually decrease the amount 
of surface CEA (93% vs 85.3%). Antigen processing and presentation in MHC-I was not directly 
assessed here, however, given the levels of TAA and HLA-A2 among the cells lines it is difficult 
to imagine SW620 and HCT116, but not Colo205 cells, enhance antigen processing and 
presentation of CEA and MUC-1 HLA-A2 restricted peptides.  Particularly when Colo205 cells 
and HCT116 cells express comparable amounts of CEA post-IR, and HCT116 cells actually 
decrease the frequency of HLA-A2 cells (Table 2.1E).  Though the impact of radiation on 
antigen processing and presentation remains under study, it is likely that altered antigen 
presentation would work in concert with other tumor changes. Increased antigen presentation in a 
toleragenic or immunosuppressive environment where robust costimulation is not present could 
still lead to sub-optimal immune responses such as T-cell anergy. All four cell lines were greater 
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than 90% positive for Pan MHC class I detected using and HLA-ABC antibody (data not 
shown), however LS174T were less than 5% positive for HLA-A2.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Sensitivity to CEA- and MUC-specific T-cell mediated cytolysis in irradiated 
colorectal tumor cells.   
 
A. HCT116 and SW620 cells treated in vitro with 0Gy (white bar), 5Gy (gray bar) or 10Gy 
(black bar) of ionizing radiation were used as targets in a 4hr CTL cytolysis assay.  At 72hr post-
IR, HLA-A2 restricted CEA-specific T cells were used as effector cells at an E:T of  25:1.  B. 
Irradiated (5Gy and 10Gy) and non-irradiated (0Gy) HCT116 and SW620 cells were used in a 
4hr lysis assays with MUC-specific T cells.  At 72hr post-IR, MUC-specific T cells were used as 
effector cells at an E:T of  25:1 (HCT116) or 12:1 (SW620).  C. Colo205 cells were used in a 
cytolysis assay with either CEA-specific or MUC-specific T cells at an E:T of 30:1. D. HLA-A2 
negative LS174T cells were used in a cytolysis assay with either CEA-specific or MUC-specific 
T cells at an E:T of 30:1.* indicates P value <0.05.  Error bars indicate variability in technical 
replicates.   Experiments were repeated at least three times with similar results.  E. Irradiated 
(10Gy) and non-irradiated (0Gy) CRC cells were cultured and subsequently stained with PE-
labeled antibodies for flow cytometry to measure surface expression of HLA-A2 and TAA 
proteins on the surface of colorectal tumor cells.  Isotype control staining of irradiated cells was 
less than 5% positive.  Numbers indicate % of cells positive and those in parenthesis indicate 
mean fluorescence intensity (MFI) of cells expressing molecule on the cell surface 72h post-
irradiation.  (-) indicates level of detection below background.  CEA= Carcinoembryonic 
antigen.  MUC=Mucin-1.  
SW620 99.5%(78) 97.6%(302) 93% 85.30% 26.90% 40.20% 
HCT116 99.5%(164) 74.6%(226) 7.19% 22.70% 3% 39% 
Colo205 99.5% (194) 99%(255) 17% 25.30% 4.70% 13.70% 
LS174T - - 85% (684) 80% (1430)  11.9 40% 
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Interaction with irradiated tumor cells enhances activation of T cells.  
     We observed increased lytic activity against irradiated tumor cells of diverse antigen 
specificity.  In this in vitro assay, the increased T-cell activity is occurring in the absence of 
accessory cells, such as antigen presenting cells, suggesting that the increased activity was a 
result of direct T-cell and tumor cell interactions.   To further define the impact that irradiated 
tumor cells were having on T cell biology, we evaluated changes in the expression of two 
markers of activation, CD69 and CD25, on the surface of T cells.  Irradiated and non-treated 
SW620 and HCT116 tumor cells were cultured and human TAA-specific T cells were 
subsequently added to the cultures.  T cells were also cultured alone, and 37.4% of these control 
T cells expressed CD25 on their surface (Fig. 2.2A).  When these T cells were co-cultured with 
non-irradiated SW620 tumor cells for 48hr, the frequency detected was 8.35%. Interestingly, 
when these T cells were incubated with SW620 cells irradiated with 5, 10 or 15Gy, CD25+CD8+ 
T-cell frequency increased to 14.4%, 19.5% and 30.1%, respectively.  This same increase in 
CD25+CD8+ T cells was observed following exposure of T cells to irradiated HCT116 cells in a 
dose dependent manner (Fig. 2.2B). More CD25+CD8+ T cells were detected if T cells were 
incubated with both 5Gy (black bar) or 10Gy (gray bar) treated HCT116 cells, than if they were 
incubated with untreated cells (white bar).  In contrast, T cells exposed to Colo205 cells did not 
display increased expression of CD25 on CD8+ cells.  In fact, expression appeared to decrease 
from 10.4% (non-irradiated) to 6.22% (5Gy) and 5.81% (10Gy).  Moreover, Colo205 cells were 
also not killed better by CTLs post-IR (Fig. 2.1C).  In these analysis the total lymphocyte 
population was analyzed based on scatter profile gating, and the total number of CD8+ cells 
(including both CD25-positive and CD25-negative cells) also appears to increase when T cells 
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are incubated with irradiated tumor cells (Fig. 2.2A).   We next gated on the CD8+ cell 
population only, and found that the frequency of CD25+ cells within the CD8+ T-cell population 
similarly increased in T cells exposed to irradiated SW620 tumor cells (24.1% in 10Gy tumor 
cells) when compared to the frequency detected in non-irradiated tumor cells (17.1%) (Fig. 
2.2C).   Moreover the loss of CD25 expression when T-cells are incubated with non-irradiated 
tumor cells remains apparent (26% expression reduced to 17.1%).  
    While the expression of CD69 was higher in our T cells cultured alone, we were still 
able to observe an increase in expression following incubation with irradiated tumor cells in both 
SW620 cells and HCT116 cells. T cells co-cultured with non-irradiated SW620 tumor cells 
contained 11.9% CD69+CD8+ (Fig. 2.2D) and this increased to 19.6% (5Gy), 26.3% (10Gy) and 
40.5% (15Gy) following co-incubation with irradiated tumor cells. 40.4% of control T cells 
cultured alone were CD69+CD8+. While T cells co-cultured with HCT116 cells displayed a 
similar increase in CD69 expression (Fig. 2.2E), those cultured with Colo205 cells again 
displayed a decrease in CD69+CD8+ cells. When only the CD8+ cells within the co-culture were 
gated and evaluated, CD69 expression increased significantly from 36.8% up to 47.2% (Fig. 
2.2F). There was no change in the expression of activation markers on MART-1 specific T-cells 
incubated with either irradiated HCT116 or SW620 cells suggesting that antigen recognition is 
required (data not shown). 
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Figure 2.2: T-cell activation is increased following exposure to irradiated colorectal tumor 
cells.  
 
1 x 103 colorectal tumor cells were irradiated with 5, 10, or 15Gy and plated in a 96-well plate 
for 48hr. 1 x 104 human CEA-specific CD8+ T cells were subsequently cultured alone or co-
cultured with the irradiated colorectal tumors for 48hr.  A. Flow cytometry plots showing the 
frequency of CD8+ CD25+ T-cell co-incubated with SW620 cells. B. The frequency of CD8+ 
CD25+ T-cell was determined by flow cytometry in HCT116 and Colo205 cell cultures. * = 
A. 
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Statistically significant relative to untreated cells by K-S.  C. Flow cytometry plots showing the 
frequency of CD25+ cells within the CD8+ cell population following co-incubated with SW620 
cells. Isotype control staining is shown in gray filled histogram.  CD25-APC positive cells are 
shown in solid black line histogram.  D. Flow cytometry plots showing the frequency of CD8+ 
CD69+ T-cell co-incubated with SW620 cells. E. The frequency of CD8+ CD69+ T-cell was 
determined by flow cytometry in HCT116 and Colo205 cell cultures.  As a control, T cells 
incubated alone were also evaluated (striped bar). * = statistically significant relative to untreated 
cells by K-S.  F. Flow cytometry plots showing the frequency of CD25+ cells within the CD8+ 
cell population following co-incubated with SW620 cells.  Isotype control staining is shown in 
gray filled histogram.  CD69-PE positive cells are shown in solid black line histogram.  
Experiments repeated three times with similar results.     
 
 
Interaction with irradiated tumor cells decreases cell death of T cells.  
We observed a significant increase in frequency of activated CD8+ T cells as well as total 
CD8+ T-cell population following incubation with irradiated tumor cells and sought to determine 
if increased T-cell survival could be responsible for this. For this, we measured apoptosis by 
7AAD staining of TAA-specific T cells following 24hr incubation with tumor cells.  Irradiation 
reduced the number of dead T cells when compared to co-incubation with non-irradiated 
counterparts, and 31.1% of T cells incubated with SW620 are dead, while only 11.4% of T cells 
incubated with SW620 cells irradiated with 10Gy are dead (Fig. 2.3A).  Very few dead cells 
were detected when T cells were incubated alone (3.4%) (Fig. 2.3B; checked bar), while there 
was a robust increase in T-cell death upon incubation with untreated HCT116 tumor cells 
(20.1%)(Fig 2.3B; white bar).   HCT116 cells also demonstrated reduced death of T cells co-
incubated with 5Gy (14.5%) and 10Gy (7.76%) irradiated tumor cells (Fig. 2.3B).  These 
findings suggest that irradiated tumor cells not only enhance the frequency of activated T cells, 
but also increase the survival of T cells.   Irradiated Colo205 tumor cells showed a reduced 
ability to promote T-cell survival (0Gy-25.4%, 5Gy-24%, 10Gy-19.4%) when compared to both 
SW620 and HCT116 cells.  The levels of active caspase-3 as a marker of T cells undergoing 
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early apoptosis following co-incubation with tumor cells was also evaluated.  Active caspase-3 
expression in CD8+ T cells was measured after 4h (Fig. 2.3C) and 18h (Fig. 2.3D) of co-culture 
with irradiated and non-irradiated tumor cells. Tumor irradiation significantly decreased the 
number of early apoptotic (active caspase-3 positive) T cells when evaluated after 18h co-
incubation (Fig. 2.3D, P<0.01), but was not significant after 4h. 
 
 
Figure 2.3: T-cell death is reduced following exposure to irradiated colorectal tumor cells.  
 
1 x 103 colorectal tumor cells were irradiated with 5Gy or 10Gy and plated in a 96-well plate for 
48hr.  1 x 104 human CEA-specific T cells were subsequently added and co-cultured with the 
irradiated colorectal tumors for 24hr.  A. Flow cytometry plots showing the frequency of 7AAD-
positive CD3+ T-cells co-incubated with SW620 cells.  B. The frequency of 7AAD-positive T 
cells (CD3+) was determined by flow cytometry in HCT116 and Colo205 cell cultures.  As a 
control, T cells incubated alone were also evaluated (checked bar).  Experiment repeated two 
times with similar results.  C. The frequency of T cells expressing active caspase-3 was 
determined by flow cytometry after 4h co-culture SW620 and HCT116 cell cultures.   D. The 
frequency of T cells expressing active caspase-3 was determined by flow cytometry after 18h co-
culture SW620 and HCT116 cell cultures.  * = statistical significance relative to untreated cells 
as determined by Probability Binning (Chi(T)) test.  * P<0.01.  Experiments repeated three times 
with similar results. 
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Sub-lethal irradiation of colorectal carcinoma cell lines enhances OX40L and 41BBL 
expression.   
      There are a number of proteins that, when expressed by target cells, can contribute to 
enhanced local activity of CD8+ cytolytic T cells through increased activation/costimulation or 
survival. Signals transduced by proteins such as 41BB, OX40, CD27 and ICOS are regarded as 
especially important for survival, expansion and effector function of T cells that have initially 
received activating signals via the CD28 receptor (Watts 2005, Kober, Leitner et al. 2008).  To 
further investigate the mechanisms underlying enhanced T-cell activation and survival, we 
examined changes in CTL effector co-stimulatory molecules, such as OX40L, 41BBL, CD70 
(CD27L/TNFSF7) and ICOSL (CD275/B7-H2) on irradiated tumor cells. A panel of colorectal 
tumor cells (HCT116, SW620, HT-29, Caco-2, Colo205 and WiDr) were irradiated, and the 
surface expression of these proteins was evaluated by flow cytometry after 48-72hr. We 
observed 18.8% of non-irradiated WiDr cells expressed OX40L, and this increased to 20.9% 
following 5Gy, and 60.9% following 10Gy (Fig. 2.4A).  The average of three replicate 
experiments in WiDr cells revealed an average increase in expression of 44% following radiation 
from 17% in cells receiving no radiation (P=0.0295).  There was a significant increase in OX40L 
expression in both HCT116 and SW620 (Fig. 2.2B).  Though radiation increased the expression 
of OX40L in HT-29 and Caco-2 cells repeatedly, it was not significant based on the average of 
replicate experiments and there was no increase in expression observed in Colo205.  Staining of 
cells with isotype control antibody was below 5% in all cells evaluated (data not shown).  We 
next evaluated the surface expression of 41BBL in the same colorectal tumor cell lines.  Figure 
2.5A shows the level of 41BBL protein on the surface of untreated WiDr cells (1.75%).  The 
level of 41BBL increases following both 5Gy (13.6%) and 10Gy (37.5%) treatment.  The 
average of three replicate experiments revealed an average increase in expression from 4% (0Gy) 
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up to 33% following 10Gy irradiation of WiDr cells, and this increase was statistically 
significant (P=0.0013).    Expression of 41BBL also increased in four of the five other tumor cell 
lines tested (Fig. 2.5B) and this increase was significant in SW620, HCT116 and Caco-2 cells.  
Again, Colo205 cells were the exception and radiation did not increase the expression of 41BBL.  
We also evaluated the longevity of increased OX40L and 41BBL and found that the elevated 
expression of 41BBL protein could still be seen seven days post-IR in WiDr, HCT116 and 
SW620 cells, and the elevated expression of OX40L was maintained in WiDr cells but not in 
SW620 cells (data not shown).  These data suggest that the modulation of these proteins in tumor 
cells by radiation can occur and be sustained.  Furthermore, we detected significantly increased 
expression of both OX40L and 41BBL mRNA in all colorectal tumor cell lines evaluated (data 
not shown), suggesting that increased gene transcription or transcript stability is responsible for 
surface protein changes. 
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Figure 2.4: Tumor cells modulate OX40L protein expression after treatment with 
radiation.  
 
A. Irradiated (5Gy and 10Gy) and non-irradiated (0Gy) WiDr colorectal carcinoma cells were 
stained with PE-labeled antibody to human OX40L.  Isotype control staining in irradiated cells 
was all less than 5% positive in all samples.  B. OX40L expression in five additional tumor cell 
lines receiving 10Gy (black bar) or 0Gy (gray bar). * indicates P value <0.05.  Data graphed are 
the mean of two (Caco2), three (HCT116, Colo205, HT-29) or four (SW620) experimental 
repeats and error bars represent the SEM across the independent experiments.  
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Figure 2.5: Tumor cells modulate 41BBL protein expression after treatment with radiation.  
 
A. Irradiated (5 and 10Gy) and non-irradiated (0Gy) WiDr colorectal carcinoma cells 
were cultured and subsequently stained with PE-labeled antibody to 41BBL.  Isotype control 
staining of irradiated cells was less than 5% positive.  B. 41BBL expression in five additional 
colorectal tumor cells lines receiving 10Gy (black bar) or 0Gy (gray bar). * indicates P value 
<0.05.  Data graphed are the mean of three (Colo205, HT-29, Caco2) or four (HCT116, SW620) 
experimental repeats and error bars represent the SEM across the independent experiments.  
 
We next wanted to evaluate if the expression of other co-stimulators of CD8+ effector cells was 
also changed in irradiated tumor cells.  For this we extended our evaluation to another TNFSF 
member, CD70, and to a B7-related protein family member, ICOSL.  No increase in either CD70 
(Fig. 2.6A) or ICOSL (Fig. 2.6B) was detected in HCT116 cells treated with 10Gy of radiation.  
This is in contrast to the increase in 41BBL detected in the same cells post-IR (Fig. 2.6C).  We 
also did not detect an increase in CD70 in any other colorectal tumor cell lines evaluated (Fig. 
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2.6D).  Furthermore, while we saw a mild increase in ICOSL expression in SW620 cells (0.2%-
0Gy versus 14.10%-10Gy), we were unable to see a change in ICOSL expression in any of the 
other tumor cell lines.   In addition, no increase in the expression of B7-1 (CD80) was observed 
following irradiation in any of the cell lines evaluated (data not shown). 
 
 
 
 
 
Figure 2.6 Expression of CD70 and ICOSL following tumor cell irradiation. 
 
A.CD70 expression (black line). B. ICOSL expression (black line). C. 41BBL expression (black 
line) 48 post-IR in HCT116 cells.  Isotype control stained cells were all less than 5% positive 
(filled grey histogram).  D. CD70 and ICOSL expression in treated and untreated SW620, WiDr, 
HT-29 and Colo205 cells.   Experiments repeated two and three times with similar results. 
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41BBL and OX40L dual co-stimulation is required for radiation-enhanced 
sensitivity to CTL killing.  
       In addition to delivering anti-apoptotic signals to T cells, Salih et al., (2000) demonstrated 
that 41BBL expression on carcinoma cells induced the production of IFN-γ in T-cell and tumor 
cell cocultures (Salih, Kosowski et al. 2000).  Moreover, OX40L and 41BBL have been reported 
to program effector function in T cells (Croft 2003, Walch, Rampini et al. 2009, Chacon, Wu et 
al. 2013), and result in effective anti-tumor immunity.  These data indicate that T-cell effector 
function could be enhanced through co-stimulation of these pathways.   Indeed, in the present 
study we detected no change in the expression of OX40L or 41BBL in Colo205 cells (Fig. 2.4B 
& 2.5B) and, interestingly, these cells also showed no enhancement of CTL killing post-IR (Fig. 
2.1C).  These results suggest that the enhanced CTL killing of irradiated tumor cells may be due 
to the enhanced expression of the co-stimulatory molecules OX40L and 41BBL.  To further 
investigate whether OX40L and 41BBL are involved in enhanced CTL killing of irradiated 
colorectal tumor cells, we performed CTL cytotoxicity assays after blocking and/or inhibiting 
these molecules.  Knocking down two genes in a single cell simultaneously using siRNA is 
technically difficult, so we chose to use a combination of siRNA gene knockdown and a 
functional blocking antibody to allow us to evaluate tumor cells in which both pathways were 
blocked.  For these experiments, the ligand-receptor interaction of OX40/OX40L was blocked 
using neutralizing antibody against human OX40L, and radiation-induced 41BBL was knocked 
down in tumor cells using homologous siRNA.  We confirmed siRNA knockdown in our cells by 
quantifying mRNA in several tumor cells.   We observed elimination of the radiation-induced 
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increase in 41BBL mRNA in HCT116 cells transfected with 41BBL-specific siRNA but not 
negative control siRNA (Fig 2.7A). Non-irradiated HCT116 cells had limited lysis by TAA 
specific CTLs and this was enhanced to 29.3% (black bar) after irradiation with 10Gy (Fig. 
2.7B).  Irradiated tumor cells knocked down for 41BBL were lysed less than irradiated tumor 
cells expressing endogenous levels of 41BBL (17.2%; data not shown); however, this lysis was 
completely lost when both 41BBL was knocked down and the OX40L blocking antibody was 
used in combination (P=0.067). Thus, radiation-enhanced killing of tumor cells was completely 
reversed when both effector co-stimulatory molecules were inhibited (Fig. 2.7B). To determine 
if OX-40L and 4-1BBL expressions could reverse radiation-enhanced T-cell survival we 
evaluated active Caspase-3 expression in T-cells co-incubated with HCT116 tumor cells for 5h. 
The flow cytometry data (Fig. 2.7C) are representative of 3 independent experiments with 
similar results and suggest that dual blockade on irradiated tumor cells increases the amount of 
T-cell death. Overall, our study reveals that radiation-enhanced tumoricidal activity of CTLs 
could be due, in part, to enhanced expression of both OX40L and 41BBL.  
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Figure 2.7 Radiation-enhanced sensitivity to T-cell mediated lysis is reduced in the absence 
of OX40L and 41BBL. 
 
Radiation-enhanced sensitivity to T-cell mediated lysis is reduced in the absence of OX-40L and 
4-1BBL. A. 4-1BBL was knocked down in tumor cells as described in Materials and Methods.   
Briefly, 1x105 HCT 116 cells were and transfected the following day with 4-1BBL siRNA or a 
control siRNA.  24hr post-transfection, the cells were irradiated with 10Gy.  24hr post-IR, cells 
were harvested and 4-1BBL mRNA was quantified.  * indicates P value <0.05 and **<0.0001.  
Data graphed are the mean of two experimental repeats and error bars represent the SEM across 
the independent experiments. B.  2x104 HCT 116 cells were plated in 24-well plates and 
transfected with 4-1BBL siRNA or a control siRNA.  After transfection, the cells were irradiated 
with 10Gy and used the next day in a Eu-release cytotoxicity assay as described in the material 
and methods.   In the indicated group, neutralizing antibody to human OX-40L was added to 
tumor cells used in the cytolysis assay. Error bars indicate variability in technical replicates.  
Experiments repeated at least two times with similar results.  C.  Flow cytometry plots showing 
active Caspase-3 expression in T-cells incubated alone or with treated HCT116 cells for 5h. * = 
statistical significance relative to indicated group by K-S.  Experiments repeated three times with 
similar results. 
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We performed a similar evaluation of SW620 cells to determine if this effect could be observed 
in more than one colorectal tumor cell line.  SW620 cells displayed a mild reduction in CTL 
killing when either 41BBL (P=0.0724) or OX40L (P=0.0379) signals were blocked and this was 
further reduced to levels similar to untreated cells when both signals were blocked (P=0.0316) 
(Fig. 2.8B).  CTL cytolysis of irradiated SW620 cells was also inhibited if 41BB signals were 
blocked using a neutralizing antibody to 41BB (on the T-cell) in combination with the OX40L 
neutralizing antibody (data not shown).  Furthermore, radiation-induced activation, as 
determined by CD25 expression, of CD8+ CTLs was reversed when dual blockade was 
performed (Fig. 2.8C).  48h after cytolysis assay set-up 48.6% of CD8+ cells expressed CD25 
when incubated with SW620 cells irradiated with 10Gy as compared to 40% of CD8+ cells 
following interaction with non-irradiated SW620 cells. When both 41BBL and OX40L signals 
were absent 42.9% of CD8+ cells expressed CD25. As a positive control, CD25 expression was 
detected on 84% of T-cells stimulated with phorbol myristate acetate (PMA) and ionomycin 
(data not shown).  
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Figure 2.8: Radiation-enhanced sensitivity to T-cell mediated lysis and T-cell activation is 
reduced in the absence of OX40L and 41BBL.  
 
A. 41BBL was knocked down in tumor cells as described in Materials and Methods.   Briefly, 
1x105 SW620 cells were and transfected the following day with 41BBL siRNA or a control 
siRNA.  24hr post-transfection, the cells were irradiated with 10Gy.  48hr post-IR, cells were 
harvested and 41BBL mRNA was quantified.   B. 2x104 SW620 cells were plated in 24-well 
plates and transfected with 41BBL siRNA or a control siRNA.  After transfection, the cells were 
irradiated with 10Gy.  48h post-IR cells were used in a Eu-release cytotoxicity assay using CEA-
specific T-cells at an E:T ratio of 30:1.  In the indicated groups, neutralizing antibody to human 
OX40L was added to SW620 cells used in the cytolysis assay. C. Supernatants were collected 
and analyzed for cytolysis at 4h.  Incubation of T-cells and tumor cells was allowed to continue 
for an additional 48h.  48h after cytolysis assay set-up, cells were harvested and stained for 
markers of T-cell activation.  Flow cytometry plots showing the frequency of CD25+ cells within 
the CD8+ cell population after incubation with irradiated SW620 cells. * indicates P value <0.05.  
Error bars indicate variability in technical replicates.   Experiments repeated at least two times 
with similar results. 
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2.5 DISCUSSION 
  There is a wide array of CIT strategies under clinical investigation in combination with 
RT for the treatment of advanced cancers.  With the exception of studies using RT for 
lymphodepletion prior to adoptive cell transfer (Dudley, Yang et al. 2008), most clinical 
investigations utilize RT as an adjuvant to immune-based therapies (Chi, Liu et al. 2005, 
Kaufman and Divgi 2005, Lechleider, Arlen et al. 2008). These studies demonstrate enhanced 
immune responses, including expanded numbers of circulating anti-tumor CTLs and antibodies 
in treated patients.  Unfortunately, these increased immune responses have not translated to a 
significant reduction in tumor burden often enough (Gulley, Arlen et al. 2005, Nesslinger, Sahota 
et al. 2007, Lechleider, Arlen et al. 2008) and the reasons for this unexpected lack of clinical 
response have yet to be resolved.  More recently, modulation of tumor cells by RT has come into 
the spotlight as it has become clear that radiation survivors likely have an altered phenotype that 
can be exploited by CIT approaches (Makinde, John-Aryankalayil et al. 2013).  Detailed 
investigation into the molecular mechanism that results in the ability of IR to enhance anti-tumor 
immune responses will be required to capitalize on these biological changes and allow for 
additional opportunities for eliminating advanced stage cancers. To our knowledge, our study 
reports for the first time that human colorectal carcinoma cells surviving radiation modulate 
expression of both OX40L and 41BBL, and that irradiated tumor cells promote CTL activation, 
survival and tumoricidal activity related to these changes. 
     Our previous CTL lysis assays were done using CTLs against single antigen 
specificity, CEA.  Here we expanded this evaluation to MUC-1 specific CTLs. Killing activity of 
both CEA-specific and MUC-specific T cells was enhanced, suggesting that radiation-enhanced 
lysis is not limited to a single antigen specificity or tumor cell line (Fig. 2.1).  We also detected 
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enhanced susceptibility to CTL killing in tumor cells treated with a lower dose of radiation (5Gy) 
than previously reported. Overall, these in vitro studies highlight the ability of irradiated tumor 
cells to directly enhance effector T-cell activity in the absence of tumor cell death (and 
subsequent induction of antigen presentation by APCs).  We have recently reported on such 
“immunogenic modulation” (occurring in the absence of “immunogenic cell death”) following 
treatment of human tumor cells with docetaxel chemotherapy (Hodge, Garnett et al. 2013). 
Utilization of such direct tumor cell to T-cell mechanisms from phenotypically altered tumor 
cells that do not die post-IR, in addition to enhanced “danger” signals from dying cells, should 
allow for synergy resulting in a more robust anti-tumor immune attack. Thus it seems plausible 
that both of these mechanisms could be rationally applied to current combination CIT and RT 
therapy designs.  
     We observed enhanced CTL activity against tumor cells treated with radiation and 
wondered if other aspects of T-cell biology were also altered.  We reasoned that T cells capable 
of surviving longer after interacting with tumor cells would be more likely to have productive 
interactions with tumor cells resulting in enhanced ability to kill tumor cells. Very few dead T 
cells were detected in cultures of T cells alone; however, there was an increase in T-cell death 
upon incubation with untreated tumor cells (Fig 2.3).  Death of T-cells following interaction with 
tumor cells has been reported by others, and is thought to be caused by tumor expressed PDL1, 
FasL and/or activation induced cell death (AICD) (Zaks, Chappell et al. 1999, Chiou, Sheu et al. 
2005, Prado-Garcia, Romero-Garcia et al. 2012).  Surprisingly, we detected a decrease in the 
number of dead T cells if the tumor cells had been treated with radiation as compared to non-
irradiated cells.  We next measured T-cell activation by evaluating changes in the expression of 
two general markers of T-cell activation, CD25 and CD69. We found that the frequency of 
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CD8+CD25+ and CD8+CD69+ T cells was increased following exposure to irradiated SW620 
and HCT116 cells, as compared to non-irradiated tumor cells (Fig 2.2).  
     Signaling through OX-40 (TNFRSF4/CD134) promotes T-cell survival and expansion 
(Garber 2011). The expression of IL2 receptor (CD25), IL7 and IL12 receptors is also up-
regulated on the surface of T cells by OX-40/OX-40L engagement (Mousavi, Soroosh et al. 
2008). 4-1BB engagements with its ligand promote survival of CD8+ T cells by up regulating 
expression of Bcl-xL and Bfl-1 (Lee, Park et al. 2002).   In addition to promoting T-cell 
proliferation and survival, 4-1BBL reactivates anergic T cells (Habib-Agahi, Jaberipour et al. 
2009). As both OX-40L and 4-1BBL have been reported to enhance T-cell survival and T-cell 
activation, we next evaluated their expression in our tumor cells.  We found that irradiating five 
of six CRC tumor cell lines increased surface expression of both OX-40L (Fig. 2.4), and 4-1BBL 
protein (Fig. 2.5) after treatment with 10Gy of ionizing radiation.  Furthermore, increased 
mRNA of both genes was also detected (Fig. 2.6), suggesting that the increase in protein 
expression was a result of increased transcription (or stability of transcripts). Though non-treated 
tumor cells expressed variable amounts of both OX-40L and 4-1BBL on their cells surface, this 
rarely exceeded 20% in our experiments.  Previous reports by Salih et al. (2000) measured 4-
1BBL expression on carcinoma cells and found that HCT116 cells expressed higher levels than 
HT-29 cells, which we also saw in our evaluation of untreated tumor cells (Fig 2.5B; gray bars 
The mechanism of selective gene expression is currently under investigation, and other data from 
our lab suggests that radiation is epigenetically regulating expression of 4-1BBL and OX-40L 
(Kumari, Cacan et al. 2013).  
      We were surprised to see that, in contrast to the lysis of irradiated HCT116 cells and 
SW620 cells, we did not observe enhanced lysis of irradiated Colo205 cells (Fig 2.1C).   It is 
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interesting that this cell line also had the lowest level of 4-1BBL expression among all the cell 
lines, and its expression was unchanged by radiation (Fig 2.5B).  The expression of OX-40L 
protein was also unchanged by radiation in these cells (Fig 2.4B). Furthermore, the number of 
activated CD8+ T cells (expressing CD25 or CD69) was not increased when T cells were co-
cultured with irradiated Colo205 cells (Fig 2.2B and 2.2D), though a modest increase of T-cell 
survival was seen (Fig. 2.3B).  These data support the hypothesis that increased expression of 
OX-40L and 4-1BBL on HCT116 and SW620 tumor cells results in enhanced T-cell activation 
and killing activity.  Other studies from our lab suggest that these genes can be increased by IR 
in other tumor cell types including both breast and prostate (Bernstein, Garnett et al. 2014).  
      Antigen processing and presentation in MHC-I was not directly assessed here, 
however, given the levels of TAA and HLA-A2 among the cells lines it is difficult to imagine 
SW620 and HCT116 enhancing antigen processing and presentation of CEA and MUC-1 HLA-
A2 restricted peptides, but not Colo205 cells.  Both HCT116 and Colo205 cells increase 
expression of CEA, MUC and HLA-A2.  However, HCT116 cells are killed post-IR while 
Colo205 cells are not.  This occurs despite the fact that Colo205 cells express more MHC 
molecules per cell (255) than HCT116 (226) cells as determined by both MFI and percent 
positive (Fig 2.1E).  SW620 cells express more MHC-I than HCT116 and were killed slightly 
better than HCT116 cells by CEA-specific T-cells, however, they actually decrease the amount 
of surface CEA. HLA-A2 negative cells (LS174T) are also not killed even though they express 
CEA and MUC and upregulate both OX-40L and 4-1BBL (data not shown). While the impact of 
radiation on antigen processing and presentation in human tumor cells remains under 
investigation, it remains likely that altered antigen presentation would work in concert with other 
tumor changes. Increased antigen presentation in a toleragenic or immunosuppressive 
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environment, where robust costimulation is not present, would still lead to sub-optimal immune 
responses.  
      To determine if radiation-induced expression of OX-40L and 4-1BBL plays a direct 
role in enhanced tumor cell susceptibility to lysis by CTLs, we conducted CTL cytolysis 
experiments in combination with molecular inhibition.  We found that neither knocking down 4-
1BBL in tumor cells, nor inhibiting OX-40L signaling independently, completely reversed 
radiation-enhanced sensitivity to cytolysis (Fig. 2.8B). However, when both molecules were 
inhibited there was a more prominent loss of the radiation-enhanced killing of both HCT116 and 
SW620 cells by T cells (Fig. 2.8C & 2.9B), and a reduction in expression of CD25 (Fig 2.8C) 
and CTL survival (Fig. 2.9C).  Both 4-1BBL and OX-40L signals have been reported by others 
to increase the production of effector molecules such as perforin and granzyme in stimulated 
CTLs (Walch, Rampini et al. 2009, Chacon, Wu et al. 2013). Whether irradiated tumors are 
impacting production or release of effector molecules from CTLs is currently under 
investigation. Ongoing mechanistic studies are evaluating which mechanism (increased survival 
or increased production/release of effector molecules or both) is primarily responsible for 
enhanced tumoricidal activity, as well as the relative contribution of each co-stimulatory 
molecule following both in vivo and in vitro tumor cell irradiation.   
      The aims of this study were meant to provide data supporting the growing use of RT in 
combination with CIT.   If IR-modulated expression of 4-1BBL and OX-40L is shown to play a 
significant role in the ability of RT to enhance effector CTL killing, this could be an alternative 
therapeutic approach to enhancing these important T-cell signals.  This approach is particularly 
relevant given the severe toxicity that can occur when using agonistic antibodies. Furthermore, 
the use of agonist antibodies is not limited to tumor-specific T-cells and, as a result, non-tumor 
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specific T cells can become activated and induce off-target effects. Using RT to induce these 
molecules specifically on a focused target represents a refinement in the approach by triggering 
these pathways in anti-tumor CTLs infiltrating irradiated tumors.  Ongoing investigations include 
determining the impact of RT on tumor modulation in vivo to assess the specificity of changes 
on tumor cells versus other cells in the microenvironment. Ultimately, if IR is shown to have a 
profound and consistent effect on CTL activity this would provide support for using IR, along 
with CIT strategies, specifically to enhance signals to these cells and optimize anti-tumor CTL 
responses. 
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3.1 ABSTRACT:  
 
Sub-lethal doses of radiation can alter the phenotype of target tissue by modulating gene 
expression and making tumor cells more susceptible to T-cell-mediated immune attack. We have 
previously shown that sub-lethal tumor cell irradiation enhances killing of colorectal carcinoma 
cells by tumor-specific cytotoxic T cells by unknown mechanisms. Recent data from our lab 
indicates that irradiation of tumor cells results in the upregulation of OX40L and 41BBL, and 
that T cells incubated with irradiated tumor cells displayed improved CTL survival, activation 
and effector activity. The objective of this current study was to determine the mechanism of 
enhanced OX40L and 41BBL expression in human colorectal tumor cells. Methods: Two 
colorectal carcinoma cell lines, HCT116 and SW620, were examined for changes in the 
expression of 41BBL and OX40L in response to inhibition of histone deacetylases (using TSA) 
and DNA methyltransferases (using 5-Aza-2′-deoxycytidine) to evaluate if epigenetic 
mechanisms of gene expression can modulate these genes. Tumor cells were treated with 
radiation, TSA, or 5-Aza-dC, and subsequently evaluated for changes in gene expression using 
RT-qPCR and flow cytometry. Moreover, we assessed levels of histone acetylation at the 41BBL 
promoter using chromatin immunoprecipitation assays in irradiated HCT116 cells. Results: Our 
data indicate that expression of 41BBL and OX40L can indeed be epigenetically regulated, as 
inhibition of histone deacetylases and of DNA methyltransferases results in increased OX40L 
and 41BBL mRNA and protein expression. Treatment of tumor cells with TSA enhanced the 
expression of these genes more than treatment with 5-Aza-dC, and co- incubation of T cells with 
TSA-treated tumor cells enhanced T-cell survival and activation, similar to radiation. 
Furthermore, chromatin immunoprecipitation experiments revealed significantly increased 
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histone H3 acetylation of 41BBL promoters specifically following irradiation. Conclusions: Full 
understanding of specific mechanisms of immunogenic modulation (altered expression of 
immune relevant genes) of irradiated tumor cells will be required to determine how to best utilize 
radiation as a tool to enhance cancer immunotherapy approaches. Overall, our results suggest 
that radiation can be used to make human tumors more immunogenic through epigenetic 
modulation of genes stimulatory to effector T-cells. 
 
3.2 INTRODUCTION: 
 Previous reports by others and us demonstrate that sub-lethal doses of radiation alter the 
expression of genes within tumor cells (Friedman 2002, Chakraborty, Abrams et al. 2003, 
Demaria, Kawashima et al. 2005). Furthermore, it has been directly demonstrated that tumor 
irradiation, as well as treatment with some chemotherapy drugs, results in increased 
susceptibility to killing of tumor cells by cytotoxic T cells (CTLs) (Chakraborty, Abrams et al. 
2003, Garnett, Palena et al. 2004, Gelbard, Garnett et al. 2006). Notably, many genes that are 
important for T-cell anti-tumor effector activity are up-regulated following treatment with sub-
lethal doses of radiation (Friedman 2002, Garnett, Palena et al. 2004, Ifeadi and Garnett-Benson 
2012). However, the mechanisms of radiation-mediated changes in the expression of such 
immune stimulatory genes are poorly understood. 
It is clear that human cells respond to DNA-damage from ionizing radiation (IR) by 
inducing the expression of a number of genes at the transcriptional level (Garnett, Palena et al. 
2004, Brzoska and Szumiel 2009, Makinde, John-Aryankalayil et al. 2013). Induction of altered 
gene expression can be due to direct cellular radiation effects or to radiation-induced changes in 
cellular milieu. Direct cellular effects appear to be regulated through parallel signaling pathways 
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that originate from the nucleus following DNA damage, as well as signaling pathways that 
originate in the cytoplasm via reactive oxygen species production (Janssens and Tschopp 2006, 
Brzoska and Szumiel 2009). These pathways induce NF-kB activation and nuclear translocation 
(Schreck, Albermann et al. 1992, Li and Karin 1998). As would be expected, DNA damage by 
IR can induce cellular stress responses, which result in activation of DNA damage repair 
pathways and apoptotic pathways (Amundson, Do et al. 1999, Ifeadi and Garnett-Benson 2012)
 Interestingly, regulation of the expression of a variety of genes, not related to known or 
typical DNA repair or apoptotic pathways, also occur (Sreekumar, Nyati et al. 2001, Friedman 
2002, Gasser and Raulet 2006). Indeed, we previously examined 23 human carcinoma cell lines 
for their phenotypic response to sub-lethal doses of IR (Garnett, Palena et al. 2004), and found 
that RT increased the expression of several genes commonly down-regulated by tumors to 
escape immune recognition and elimination (Kojima, Shinohara et al. 1994, Zamai, Rana et al. 
1994, French and Tschopp 2002, Bubenik 2003, Modrak, Gold et al. 2003, Slavin-Chiorini, 
Catalfamo et al. 2004), including Fas (CD95), Intercellular adhesion molecule-1 (ICAM-
1/CD54), tumor associated antigens (TAA) and major histocompatibility (MHC)-Class I. Most 
recently we found that radiation enhances the expression of OX40 ligand 
(OX40L/TNFSF4/CD134L/CD252) and 41BB ligand (41BBL/TNFSF9/CD137L), important co- 
stimulators of effector CTLs on tumor cells (submitted manuscript). 
To elicit an effective immune response against tumors, T cells need to recognize tumor 
antigens presented by MHC in conjunction with appropriate co-stimulation (Kroczek, Mages et 
al. 2004, Jensen, Maston et al. 2010). In the absence of proper co-stimulation, these anti-tumor T 
cells become anergic. Proteins such as 41BBL and OX40L represent important co-stimulators of 
effector CTL activity (Curtsinger, Lins et al. 2003, Watts 2005, Mescher, Curtsinger et al. 2006, 
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Kober, Leitner et al. 2008), and we have seen sub-lethal doses of radiation increase their 
expression in human tumor cells; however, the mechanisms regulating radiation-enhanced 
modulation of the expression of these two genes remain unclear. OX40 (TNFRSF4/CD134) was 
originally characterized as a transiently expressed co-stimulatory molecule regulating CD4 and 
CD8 immunity (al-Shamkhani, Birkeland et al. 1996), and signaling through OX40 promotes T-
cell survival and expansion (Garber 2011). 41BBL co-stimulation of 41BB (TNFRSF9/CD137) 
on tumor-specific T cells is important for T-cell proliferation (Waller, McKinney et al. 2007, 
Habib-Agahi, Jaberipour et al. 2009), cytokine production and activation (Curran, Kim et al. 
2011). Engagement of OX40 and 41BB by agonist antibodies increases immunity against 
tumors, resulting in long-term survival (Pan, Zang et al. 2002) in a number of murine tumor 
models (Melero, Shuford et al. 1997, Murata, Ladle et al. 2006). Recent evidence indicates that 
the expression of 41BBL is transcriptionally activated by HDAC inhibitors in leukemia cell lines 
(Vire, de Walque et al. 2009), and that HDAC11 plays an essential role in regulating OX40L 
expression (Buglio, Khaskhely et al. 2011). Interestingly, radiation has been shown to inhibit the 
expression of HDAC1 and HDAC2 (Han, Zhang et al. 2012), and we have seen enhanced 
cytolysis by T-cells following tumor irradiation. Thus, epigenetic mechanisms may be at work 
during radiation-enhanced susceptibility to T-cell killing. 
 Epigenetic changes such as histone modifications and DNA methylation play 
important roles in regulating gene expression. DNA methyltransferase enzyme (DNMT1) adds 
methyl group to cytosine residue (Gal-Yam, Saito et al. 2008). DNA hypermethylation of CpG 
dinucleotides accumulates in promoter regions of genes and contributes to their loss through 
epigenetic silencing. Promoter hypermethylation and genome-wide hypomethylation alters genes 
expression in colorectal cancer (Cheng, Pincas et al. 2008). It has been found that genes having 
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hypermethylation also exhibit altered acetylation and methylation of histones (Kouzarides 2007). 
Histone acetylation via histone acetyltransferases (HATs) is another major epigenetic mechanism 
controlling gene expression (Roth, Denu et al. 2001, Seo, McNamara et al. 2001, Eberharter and 
Becker 2002). Gains in histone acetylation neutralize the positive charge on lysine residues and 
contribute to disrupted nucleosome structure, allowing unfolding of DNA, increased 
transcription factor access and enhanced gene expression (Richon, Sandhoff et al. 2000, Dion, 
Altschuler et al. 2005, Choudhary, Kumar et al. 2009). HDACs remove acetyl groups from 
histones and return DNA to a less accessible conformation, thereby decreasing transcription 
(Kadosh and Struhl 1997, Glozak and Seto 2007, Wang, Zang et al. 2009). Alterations in HAT 
and HDAC activity have been identified in many human cancers (Marks, Rifkind et al. 2001, 
Barneda-Zahonero and Parra 2012). HDAC inhibitors (HDACi) therefore promote 
hyperacetylation of histones, which in turn leads to chromatin relaxation and selective expression 
of genes. 
The roles of DNA methylation and histone acetylation in the expression of OX40L and 
41BBL in response to radiation have not been investigated. Hence, we designed the present study 
to test the hypothesis that irradiation leads to increased expression of OX40L and 41BBL in 
colorectal tumor cells via epigenetic regulation. We measured the expression of effector CTL co-
stimulatory molecules OX40L and 41BBL on human colorectal tumor cells lines after treatment 
with trichostatin (TSA) and 5-Aza-2′-deoxycytidine (5-Aza-dC). Ours is the first study to report 
that a) OX40L and 41BBL expression increases in CRC cells when DNMTs are inhibited, b) 
expression of OX40L and 41BBL increases in human CRC cells when HDACs are inhibited, c) 
HDAC inhibition in CRC cells can increase the activation and survival of T cells, and d) 
radiation treatment of tumor cells results in epigenetic modification of the histones in the 
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promoter of the costimulatory gene 41BBL. The use of ionizing radiation to specifically enhance 
cancer immunotherapy (CIT) strategies through epigenetic modulation of genes stimulatory to 
CTLs will have a broad impact on cancer therapy approaches and will extend the use of radiation 
into new directions. 
 
3.3 METHODS: 
 Cell lines: Human colorectal carcinoma cell lines HCT116 cells were obtained from the 
laboratory of tumor immunology and biology, NCI, NIH. The cell line SW620 was kindly 
provided by Zhi-Ren Liu (Wang, Gao et al. 2013) from Georgia State University, Department of 
Biology. All cells were cultured as recommended by ATCC and tested periodically to ensure 
absence of Mycoplasma. Cells were incubated at 37°C incubator with 5% CO2. 
Reagents: 5-Aza-2′-deoxycytidine (5-Aza-dC) and Trichostatin A (TSA) were purchased 
from Sigma-Aldrich (St. Louis, MO). Antibodies recognizing histone H3 and acetylated histone 
H3 were from Millipore (Lake Placid, NY). 
Irradiation: A RS-2000 biological X-ray irradiator (Rad source technology, Suwanee, 
GA) was used to irradiate tumor cells. Cells were irradiated at a dose rate of 2Gy/min by setting 
irradiator voltage and current at 160kV and 25mA, respectively. Cells were maintained in 
suspension and kept on ice during irradiation. Immediately after irradiation, the culture media 
was replaced with the fresh media. 
Quantitative real time PCR: RNA was extracted from tumor cells using RNeasy mini 
kit (Qiagen Inc. Valencia, CA) according to manufacturer’s instructions. Purified RNA was 
DNase- treated by Rnase-free DNase (Qiagen Inc. Valencia, CA) following manufacturer’s 
instructions. Expression of OX40L and 41BBL mRNA was determined using real time RT-PCR. 
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cDNA was synthesized using 500ng of mRNA. Amplification of cDNA was done using 
DyNaAmo cDNA synthesis kit (Finnzymes. Vantaa, Finland). Quantitative RT-PCR was 
conducted using TaqMan gene expression assay (Applied Biosystems; OX40L; Hs00967195, 
41BBL; Hs00169409, and HPRT; Hs99999909) according to manufacturer’s protocol. PCR 
thermal cycling condition was 50°C for 2min, 95°C for 10min, 40 cycles of 95°C for 15sec and 
60°C for 1min in a total volume of 20 μl/reaction. Data were collected using a 7500 Real Time 
PCR System. All samples were run in duplicate. The expression level of each gene was 
normalized over non-irradiated samples. HPRT was used as an endogenous gene whose 
expression was unaltered by treatment. Data were analyzed using the comparative Ct method 
(Livak and Schmittgen 2001). 
 Flow cytometry: Cells were stained with primary labeled mAb CD137L (41BBL)-PE, and 
CD252 (OX40L)-PE purchased from BioLegend (Sen Diego, CA). Surface staining was done in 
cell staining buffer for 30min on ice. Flow cytometry data were acquired on BD Fortessa and 
analyzed with FlowJo software (TreeStar, version 9.6). Isotype control was kept less than 5% in 
all the samples. Expression was considered increased if the absolute percent positive population 
increased by 10% or greater. 
 Chromatin Immunoprecipitation (ChIP) Assay: ChIP assays were performed as 
previously described (Ali, Cacan et al. 2013). Briefly, 48h after irradiation (10Gy) and TSA 
(250nM) treatment cells were seeded at a density of 2.0 x 106 and crosslinked with 1% 
formaldehyde. The crosslinking reaction was stopped by the addition of 0.125 M glycine. Cell 
nuclei were isolated and concentrated by lysing in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 
mM Tris pH 8.0, plus protease inhibitors) on ice followed by flash freezing in liquid nitrogen. 
Cell nuclei were sonicated using a Bioruptor to generate an average of 500 bp of sheared DNA; 
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DNA shearing was confirmed by subjecting lysates to agarose gel electrophoresis. Sonicated 
lysates were then precleared with salmon-sperm/agarose beads (Upstate) and 5% of the total 
lysate was stored as input for normalization. Half of the remaining lysate was 
immunoprecipitated with control antibody, and the other half was immunoprecipitated with 5μg 
of indicated antibody overnight at 4°C. Following an additional two hour immunoprecipitation 
with salmon-sperm/agarose beads, all samples were washed with each of the following buffers: 
low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM NaCl), 
high salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 500mM NaCl), 
LiCl buffer (0.25M LiCl, 1% NP40, 1% DOC, 1mM EDTA, 10mM Tris pH 8.0), and 1xTE 
buffer. DNA was eluted with SDS elution buffer (1% SDS, 0.1M NaHCO3) and then cross-links 
were reversed overnight with 5M NaCl at 65°C and immunoprecipitated DNA was isolated using 
phenol:chloroform:isopropanol mix (Invitrogen) as per the manufacturer’s instructions. Isolated 
DNA was quantified by real time PCR on an ABI prism 7900 (Applied Biosystems, Foster City, 
CA) using the following primers and probe for 4-1BBL: forward, 5’- GCA CGC ATA GAC 
ATA AAT TGG C-3’, reverse, 5’-TCT GTG TCT CCC CGT TAA C -3’ and probe, 5’-TCC 
ACC CAC TGC AGA GGC AAT CAA-3’; for GAPDH: forward, 5’-AAT GAA TGG GCA 
GCC GTT A-3’, reverse, 
5’-TAG CCT CGC TCC ACC TGA CT-3’ and probe, 5’-CCT GCC GGT GAC TAA CCC TGC 
GCT CCT-3’; and for CIITA: forward, 5’-CAG TTG GGA TGC CAC TTC TGA-3’, reverse, 5’- 
TGG AGC AAC CAA GCA CCT ACT-3’ and probe, 5’-AAG CAC GTG GTG GC-3’. Values 
generated from real time PCR reactions were calculated based on standard curves generated, 
were run in triplicate reactions and were analyzed using the SDS 2.0 program. 
Generation TAA-specific cytotoxic T-lymphocytes: PBMCs from HLA-A2+ donors 
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were purchased from Hemacare (Van Nuys, CA) for the generation of antigen specific CTLs as 
described elsewhere (Tsang, Zaremba et al. 1995, Tsang, Zhu et al. 1997, Garnett, Palena et al. 
2004). These leukopheresis samples, derived from HLA-A2+ patients, were obtained from 
Hemacare with appropriate informed consent. The use of these de-identified and commercially 
purchased tissues is under a human investigation protocol approved by the GSU IRB (exempt 
approval #H13305). Briefly, PMBCs were allowed to adhere to T150 flask for 2hr in AIM-V 
media. After 2hr, non-adherent cells were removed for lymphocyte isolation. Adherent cells 
were cultured for seven days in the presence of 100ng/ml of human granulocyte colony 
stimulating factor (GM-CSF) and 20ng/ml of IL-4 (Miltenyi Biotec, Inc. Auburn, CA) in AIM-V 
media and 500ng/ml CD40L (Millipore corporation, Temecula, CA) was added on day five to 
mature the DCs. On day seven DCs were collected and pulsed with 40μg/mL of HLA-A2 
binding CEA peptide (YLSGANLNL (CAP-1; (Tsang, Zhu et al. 1997)),) peptide for 4hr in a 
37°C 5% CO2 incubator. Unused DCs were frozen and stored in liquid nitrogen for 
subsequent restimulations. DCs loaded with peptide were subsequently irradiated with 50Gy. 
Immunomagnetic beads (Miltenyi Biotec Inc. Auburn, CA) were used to isolate CD8+ T cells 
from the non-adherent cells, following manufacturer instructions. Subsequently, isolated CD8+ T 
cells were co-cultured with peptide pulsed DCs. IL-7 (Millipore, Temecula, CA) at 10ng/ml and 
IL2 (Millipore, Temecula, CA) at 30U/ml were added to each well on the first and third day, 
respectively. T-cells were restimulated in this manner weekly using mature autologous DCs. 
Restimulated T cells were isolated over ficoll on day seven of culture, and used in a T-cell 
activation and survival assays. 
T-cell activation and survival assay: 1 × 103 colorectal tumor cells were irradiated or 
treated with TSA and plated in 96-well plate for 48hr. 1×104 human CEA specific CD8+ T cells 
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were subsequently added and co-cultured with the colorectal tumor cells for 48hr. The percent of 
CD8+ T cells expressing CD69 or CD25 was measured by flow-cytometry. In parallel 
experiments, 7AAD was used to measure T-cell death. Flow cytometry data were acquired on 
BD Fortessa and analyzed with FlowJo software (TreeStar, version 9.6). The live cells 
population was gated on the FSC and SSC scatter plots for analysis of surface proteins. No live 
cells gate was used for cell death analysis samples. T cell stimulation for 24h using a (1X) 
cocktail of PMA and ionomycin (eBioscience) was used as a positive control for activation of 
TAA-specific T-cells. Statistical Analysis: Statistical differences between groups were 
calculated using un-paired two-tailed student T-test and calculated at 95% confidence using 
Graphpad by Prism. P-values less that 0.05 were considered statistically significant. 
 
3.4 RESULTS: 
OX40L and 41BBL transcripts increase when DNMTs and HDACs are inhibited. 
Exposure of human carcinoma cell lines to sub-lethal radiation results in enhanced 
susceptibility to lysis by tumor specific cytotoxic T cells (CTLs) (Garnett, Palena et al. 2004, 
Gelbard, Garnett et al. 2006), and co-stimulatory proteins such as 41BBL and OX40L represent 
important regulators of effector CTL activity (Kroczek, Mages et al. 2004, Mescher, Curtsinger 
et al. 2006). These ligands for OX40 (OX40L/CD134L) and 41BB (41BBL/CD137L) are 
normally expressed on antigen presenting cells and activated endothelial cells (Liang, Gonzales 
et al. 2002, Dubovsky, McNeel et al. 2009). However, we have recently demonstrated expression 
of both proteins on tumor cells following treatment with radiation (submitted manuscript). 
Others have reported that changes in DNA methylation can upregulate the expression of 
costimulatory proteins in human tumor cells. The dynamics of the induction of DNA methylation 
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in irradiated tissue is currently unknown, and the role of methylation in expression of co-
stimulatory molecules in response to radiation has not been investigated. We began our 
investigation by treating cells with 5-Aza-2′-deoxycytidine (5- Aza-dC) to inhibit DNA 
methylation in order to determine if this would alter expression of 41BBL or OX40L in human 
CRC cells. 5-Aza-dC is a DNA methyltransferase inhibitor (DNMTi) and is incorporated into 
DNA resulting in the rapid loss of DNA methyl transferase activity (Kane, Loda et al. 1997). The 
human colorectal cell line HCT116 was treated with 5-Aza-dC for 48 or 72hr, and OX40L and 
41BBL mRNA was quantified. OX40L mRNA increased 1.4-fold (Fig. 3.1A) and 41BBL 
mRNA increased approximately 2-fold (Fig. 3.1B) at both 48 and 72hr post-treatment with 5-
Aza-dC. OX40L mRNA increased over time in tumor cells treated with radiation, as there was 
a 2.3-fold increase at 48hr and a 3.6-fold increase at 72hr (Fig. 3.1A). Radiation induced a 
similar increase in 41BBL transcript levels. Interestingly, this temporal increase was not 
observed in tumor cells treated with 5-Aza-dC as relatively equal levels of both OX40L and 
  
41BBL mRNA were detected after 48hr (gray bar) and 72hr (black bar) drug treatment. 
Moreover, the level of OX40L mRNA in cells treated 5-Aza-dC never exceeded those observed 
72h post-IR. HDACs enzymes remove acetyl groups from histones and suppress gene 
transcription. Recent studies have shown that HDAC inhibitors also have immune-modulatory 
properties, such as increasing expression of HLA-DR, ICAM-1 and B7-2 in acute myeloid 
leukemia cell lines (Maeda, Towatari et al. 2000). We next asked if inhibition of HDACs would 
result in increased expression of OX40L and 41BBL similar to the increase seen in radiation-
treated cells. For these experiments we used Trichostatin A (TSA), an inhibitor of the class I and 
class II family of HDAC enzymes, and evaluated OX40L and 41BBL mRNA expression. 
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HCT116 cells treated with TSA for 48hr (gray bar) contained more OX40L (Fig. 3.1A) and 
41BBL mRNA (Fig. 3.1B) as compared to cells treated with 5-Aza-dC for 48 or 72hr. Messenger 
RNA levels decreased after 72hr (gray bar) of TSA treatment; we note that these cells were 
sensitive to TSA toxicity and began dying after 48hr TSA treatment though this loss of viability 
did not reach significance (Fig. 3.1C). It is likely that mRNA expression at 48 and 72h is not 
representative of early radiation events. As changes in promoter activation are often an early 
event we next evaluated cells at 8 and 24h post- treatment. We found no significant increase in 
OX40L mRNA. Surprisingly, while radiation did not induce a significant increase in 41BBL 
RNA at 8 or 24h, TSA did at both time points (Fig. 3.1). Indeed the increase in 41BBL mRNA at 
24h (4-fold) exceeded levels observed after 48h treatment (Fig. 3.1B). 5-Aza-dC began to 
increase 41BBL as early as 24h after treatment by slightly greater that 2-fold (Fig. 3.1E) and this 
increase was maintained during 48 and 72h treatment (Fig. 3.1B). However, both radiation and 
TSA induced more 41BBL mRNA than 5-Aza-dC at their respective times of maximum 
induction. Overall, inhibition of both HDACs and DNMTs increased the levels of OX40L and 
41BBL mRNA in HCT116 cells. 
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Figure 3.1  5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA in 
HCT116 cells. 
 
(A) OX40L, and (B) 41BBL mRNA level was quantified using real time qPCR as described in 
Materials and Methods. Cells were plated and treated with 5AZA-dC (20uM), TSA (500nM) or 
10Gy radiation (IR). Untreated control cells were cultured with the equivalent amount of DMSO 
present in drug treated samples. Adherent cell were collected and relative levels of OX40L and 
41BBL transcripts were normalized to expression of an endogenous unchanging housekeeping 
gene. 48 (gray bar) and 72hr (black bar) mRNA values were compared to the level of gene 
expression see in untreated control samples (white bar), which was set to 1. The mean of data is 
graphed with SEM and the p-values are based on technical replicates. Experiments were repeated 
at least three times with similar results. (C) Cells were plated and untreated (DMSO) or treated 
with 5AZA-dC (20uM), TSA (500nM, 250nM or 125nM) or 10Gy radiation (IR). Both floating 
and adherent cells were collected after 48h of treatment and tumor cell viability was determining 
by trypan blue dye uptake. The mean of three separate experiments is graphed with SEM and the 
p-values are based on combined data from separate experiments. (D) OX40L and (E) 41BBL 
mRNA level was quantified. Eight (gray bar) and 24hr (black bar) mRNA values were compared 
to the level of gene expression see in untreated control samples (white bar). The mean of data is 
graphed with SEM and the p-values are based on technical replicates. Experiments were repeated 
at least three times with similar results. (F) Cells were plated and untreated (DMSO) or treated 
with 5AZA-dC (20uM), TSA (500nM, 250nM or 125nM) or 10Gy radiation (IR). Adherent cells 
were collected after 24, 48, and 72h of treatment and live tumor cell number was determining 
using a cell counter. The mean of three separate experiments is graphed with SEM and the p-
values are based on combined data from separate experiments. Significant P-value shown in 
the indicated groups was determined at 48h. *indicates P value of <0.05, **indicates P value of 
<0.001. 
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To determine if epigenetic regulation of these genes was a common mechanism observable in 
carcinoma cells, we evaluated a second human CRC cell line, SW620. Again, SW620 cells were 
treated with 5-Aza-dC and TSA for 48 or 72hr and mRNA expression was measured by qRT-
PCR. Overall, SW620 cells were more responsive to these treatments than HCT116 cells. 5-Aza-
dC upregulated the expression of OX40L by 5.3 fold (Fig. 3.2A) and 41BBL by 3.5 fold (Fig. 
3.2B) in SW620 cells treated for 72hr (gray bar). HDAC inhibition by TSA robustly altered the 
expression of 41BBL mRNA resulting in a 25-fold increase (Fig. 3.2B), and again resulted in a 
more modest upregulation of OX40L by 1.8-fold in SW620 cells treated for 72hr (Fig. 3.2A). 
Interestingly, these cells were more sensitive to TSA toxicity (Fig. 3.2C) and displayed 
significantly reduced cell numbers following 48 and 72h treatment with TSA concentrations 
ranging from 500nM to 125nM (Fig. 3.2F). Viable cell numbers decreased with TSA treatment 
time and dose (Fig. 3.2C), however, RNA was isolated and analyzed from the adherent and 
viable cells remaining in the culture (Fig. 3.2F) for our experiments (Fig. 3.2A & 3.B). 
Moreover, we observed similar cell numbers remaining between the treatment groups after 24h 
treatment with TSA and next evaluated changes in gene expression after 8 and 24h treatment. 
Increased message for OX40L could be detected as early as 24h in cells treated with radiation 
and 5-Aza-dC (Fig. 3.2D) and was further increased after 48 and 72h (Fig. 3.2A). The largest 
increase in OX40L in response to TSA treatment in SW620 cells was detected following 
treatment for 8h (2.7-fold) and was reduced slightly thereafter (2.1-fold). We also evaluated 
41BBL expression after 8 and 24h treatment. No significant change in 41BBL mRNA was 
observed at either of the earlier time points in cells treated with 5-Aza-dC or radiation. In 
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contrast, a significant and robust increase in 41BBL expression could be detected after both 8 
and 24 hr TSA treatment (20-fold) (Fig. 3.2E) that was further increased after 72hr treatment 
(Fig. 3.2B). We noted that the relative level of 41BBL mRNA in untreated control cells appeared 
to be higher than OX40L mRNA levels in both cell lines evaluated. Overall, the largest increases 
in mRNA were detected for 41BBL mRNA following treatment of CRC cells with TSA. We also 
found that TSA induced robust mRNA changes at earlier times of treatment (8h and 24h) while 
radiation-induced changes took longer and were greatest at later times of treatment (48h and 
72h). 
Following tumor cell irradiation only adherent and proliferating cells were harvested for 
analysis. We have previously demonstrated that irradiated tumor cells continue to proliferate and 
remain viable using this method (Ifeadi and Garnett-Benson 2012) (Fig. 3.1C & 3.2C). HCT116 
cells appear to be less sensitive to TSA than SW620 cells as significantly reduced proliferation 
of treated HCT116 cells was detected only when the highest dose of TSA (500nM) was used 
(Fig. 3.1F). In contrast to TSA, there was very little impact of 5-Aza-dC on viability of tumor 
cells 48h after treatment in either cell line (Fig. 3.1C & 3.2C). Though cell numbers were slightly 
reduced following 5-Aza-dC treatment of SW620 cells this was not significant (Fig. 3.2F). 
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Figure 3.2  5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA in 
SW620 cells. 
 
 (A) OX40L, and (B) 41BBL mRNA level was quantified in SW620 tumor cells. Cells 
were plated and treated with 5AZA-dC (20uM), TSA (250nM) or 10Gy radiation (IR). Untreated 
control cells were cultured with the equivalent amount of DMSO present in drug treated samples. 
Adherent cell were collected and relative levels of OX40L and 41BBL transcripts were 
normalized to expression of an endogenous unchanging housekeeping gene. 48 (gray bar) and 
72hr (black bar) mRNA values were compared to the level of gene expression see in untreated 
control samples (white bar), which was set to 1. The mean of data is graphed with SEM and the 
p-values are based on technical replicates. Experiments were repeated at least three times with 
similar results. (C) Cells were plated and untreated (DMSO) or treated with 5AZA-dC (20uM), 
TSA (500nM, 250nM or 125nM) or 10Gy radiation (IR). Both floating and adherent cells were 
collected after 48h of treatment and tumor cell viability was determining by trypan blue dye 
uptake. The mean of three separate experiments is graphed with SEM and the p- values are based 
on combined data from separate experiments. (D) OX40L and (E) 41BBL mRNA level was 
quantified. Eight (gray bar) and 24hr (black bar) mRNA values were compared to the level of 
gene expression see in untreated control samples (white bar). The mean of data is graphed with 
SEM and the p-values are based on technical replicates. Experiments were repeated at least three 
times with similar results. (F) Cells were plated and untreated (DMSO) or treated with 5AZA-dC 
(20uM), TSA (500nM, 250nM or 125nM) or 10Gy radiation (IR). Adherent cells were collected 
after 24, 48, and 72h of treatment and live tumor cell number was determining using a cell 
counter. The mean of three separate experiments is graphed with SEM and the p-values are based 
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on combined data from separate experiments. Significant P- value shown in the indicated TSA-
treatment groups was determined at 48h. *indicates P value of <0.05, **indicates P value of 
<0.001. 
 
 
Surface expression of OX40L and 41BBL protein increases when DNMTs and HDACs are 
inhibited. 
The largest increase in mRNA was detected in SW620 cells treated with 5-Aza-dC (OX40L, Fig. 
3.2A) or TSA (41BBL, Fig. 3.2B), and we wanted to determine if increased protein expression 
also occurred. There was no significant difference in the total cell number (Fig. 3.2F) or the 
viability (data not shown) of SW620 cells following 24h hour treatment with 125nM TSA. As 
such, we evaluated surface expression of 41BBL protein by flow cytometry after 24hr treatment 
with either TSA (125nM) or 5-Aza-dC. Untreated SW620 cells expressed modest amounts of 
41BBL on the surface (38.4%), and as expected radiation increased the frequency to 60.4% (Fig. 
3.3A). Treatment with 5-Aza-dC had less of an impact on protein expression and 48% of cells 
expressed 41BBL after treatment with the drug (Fig. 3.3C). In contrast, TSA had a much larger 
impact on protein expression and, similar to radiation-induced expression, 61% of TSA- treated 
SW620 cells expressed 41BBL (Fig. 3.3D) (66% in cells treated with 500nM). Thus, relative 
changes in 41BBL protein expression (Fig. 3.3A) and 41BBL mRNA quantities (Fig. 3.2B) were 
similar in this cell line. We next evaluated OX40L protein expression. SW620 tumor cells 
increased surface OX40L following exposure to 10Gy of radiation (IR; 46.4%), as compared to 
untreated cells (DMSO; 23.1%) (Fig. 3.3E). TSA increased protein expression of OX40L to a 
similar magnitude (46.7%) as irradiated cells. Again, as seen with 41BBL, there was a smaller 
increase in surface OX40L detected (31.1%) following treatment with 5-Aza-dC. This was 
surprisingly low given the 3- to 5-fold increase in OX40L mRNA seen in these cells upon 5-Aza-
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dC treatment (Fig. 3.2A & 3.2D). Thus, mRNA modulation of the two genes (Fig. 3.2) was 
similar to protein changes by TSA and radiation (Fig. 3.3), but not 5-Aza-dC. Furthermore, the 
modulation of OX40L protein was less robust than that observed for 41BBL protein in SW620 
cells (Fig. 3.3B-3.3D & 3.3F-H). 
Overall, our results show that TSA-treated cells demonstrated the largest increase in 
protein expression, and the increase was at least as good as that observed following treatment 
with radiation (Fig. 3.3). As such, we focused our subsequent experiments on the impact of 
TSA HDAC inhibition on co-stimulatory molecule expression. Our data reveal increased 
expression of OX40L (53.2%) 48hr after irradiation of HCT116 cells as compared to untreated 
(0Gy) cells  (30.7%) (Fig. 3.4A-B & 3.4E). Expression of OX40L is detected on the surface of 
56.6% TSA- treated HCT116 cells (Fig. 3.4F) as compared to expression in control (DMSO) 
cells (38.2%). Expression of 41BBL was also enhanced to much greater levels following 
treatment with both IR (43.6% 10Gy) (Fig. 3.4C-D & 3.4E) and TSA (58.6%-250nM TSA 
versus 23%-untreated) at 48hr (Fig. 3.4G). The relative change in 41BBL surface expression 
compared to untreated cells was larger that the change in OX40L following TSA treatment in 
HCT116 cells (Fig. 3.4H). Elevated levels of these co-stimulatory proteins could still be detected 
after 3- to 4-days of TSA treatment and radiation-induced changes where greater after 72h (data 
not shown). Overall, both HCT116 and SW620 cells showed a more robust increase in 
expression of 41BBL as compared to OX40L protein expression upon TSA treatment. 
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Figure 3.3 TSA and ionizing radiation increase surface expression of co-stimulatory 
molecules in SW620 cells more than 5AZA. 
 
 (A-D) 41BBL, and (E-H) OX40L protein expression on the surface of SW620 cells was 
evaluated by flow cytometry. Cells were either untreated (DMSO), or treated with 5-Aza-dC 
(20uM), TSA (125nM) or 10Gy radiation (IR). Adherent cells were harvested 24hr post 
treatment, and stained with PE-labeled antibody to human OX40L or 41BBL. Isotype control 
stained cells were analyzed for each treatment group individually and set to 5% positive. Isotype 
control staining is shown as the gray filled histogram and protein specific staining is shown as 
black line histogram for the FACS plot data graphed in A and E. Experiments were repeated 
twice with similar results 
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Figure 3.4 TSA and ionizing radiation treated HCT116 cells increase surface levels of 
41BBL protein more than OX40L protein. 
 
(A, B and F) OX40L, and (C, D and G) 41BBL protein expression on the surface of HCT116 
cells was evaluated by flow cytometry. (E) Cells were untreated (0Gy) or treated with 10Gy 
radiation (IR). (H) In separate experiments HCT116 cells were untreated (DMSO) or treated with 
either TSA (250nM). After 48hr, cells were collected and stained with PE-labeled antibody to 
either OX40L and 41BBL. Control cell staining with a non-specific isotype control antibody was 
less than 5% positive. Isotype control staining is shown as the gray filled histogram and protein 
specific staining is shown as black line histogram for the FACS plot data graphed in E and H. 
Dotted line histogram in F and G indicates specific protein expression in untreated cells. Values 
shown on histograms are for treated cells and untreated and treated values are displayed 
graphically in H for comparison. Experiments were repeated three times with similar results 
70 
Radiation increases Histone H3 acetylation at the 41BBL promoter. 
Our data indicates that 41BBL and OX40L are epigenetically regulated and radiation 
increases expression of these genes in CRC cell lines. Histone acetylation facilitates transcription 
initiation by loosening interactions between the histones and DNA. Whereas, HDACs remove 
these acetyl groups from histones which reduces transcription. We observed that inhibition of 
HDACs by TSA increased 41BBL mRNA expression and surface protein levels in tumor cells. 
We observed that radiation increase 41BBL gene expression in a similar manner but was more 
robust at later times during treatment. As radiation has been reported to inhibit HDACs (Han, 
Zhang et al. 2012), we next wanted to determine if radiation could be increasing 41BBL 
expression by promoting increased promoter histone acetylation. To explore whether histone 
modifications are regulated in part by radiation, we assessed levels of histone acetylation at the 
41BBL promoters using chromatin immunoprecipitation (ChIP) assays in both non-radiated and 
irradiated HCT116 cells. We evaluated promoter acetylation at 48h post-IR when radiation-
induced changes in mRNA levels were robust (Fig. 3.1). TSA-treated HCT116 cells were used as 
a positive control for 41BBL promoter acetylation. As TSA inhibits HDAC activity, we expect to 
see robust increases in histone acetylation status following TSA treatment. As expected, Figure 
3.5A shows increased acetylation at the 41BBL promoter following TSA treatment (gray bar) as 
compared to untreated control cells (white bar). Surprisingly, acetylated H3 histone levels were 
significantly higher at 41BBL promoters in irradiated cells (black bar). In contrast, similar levels 
of acetylated histone H3 were associated with the GAPDH promoter in both untreated and 
irradiated HCT116 cells (Fig. 3.5B). Moreover, total levels of histone H3 were similar at 41BBL 
and GAPDH promoters revealing that there was no global change in overall histone levels (data 
not shown). These data indicate that radiation increases 41BBL expression by increasing histone 
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acetylation. To determine if radiation non-specifically increases histone acetylation levels at 
other genes, histone H3 ChIP assays were performed on the Class II Transactivator (CIITA) 
promoter IV. Histone H3 acetylation levels were similar for non-irradiated, irradiated and TSA 
treated cells at CIITA promoter IV (Fig. 3.5C), which suggests gene-specificity for radiation-
induced 41BBL promoter acetylation, likely via HDAC inhibition. 
 
 
 
Figure 3.5 Histone acetylation at 41BBL promoters in non-radiated and irradiated cells. 
 
ChIP assays were carried out in non-irradiated, irradiated (10 Gy), and TSA-treated HCT116 
cells. Following 48h of TSA treatment (250nM), lysates were immunoprecipitated with control 
antibody or with anti-acetyl histone H3. Associated DNA was isolated and analyzed via real time 
PCR using primers spanning the 41BBL, GAPDH and CIITA promoters. Real-time PCR values 
were normalized to the total amount of promoter DNA added (input). Input values represent 5% 
of the total cell lysate. Values represent mean ± SEM of three independent experiments. 
**P<0.005. A. Global levels of Histone H3 acetylation associated with the 41BBL promoter. B. 
Global levels of Histone H3 acetylation associated with the GAPDH promoter. C. Global levels 
of acetylated Histone H3 associated with the CIITA promoter. 
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Figure 3.6 : Enhanced survival of T-cells co-incubated with CRC tumor cells treated with 
TSA.  
 
SW620 and HCT116 cells were treated with DMSO, TSA (250uM), or radiation (10Gy). After 
48hr, tumor cell were harvested and co-cultured with human CEA-specific CD8+T-cells for 
another 48hr. Cell death was also measured in CD8+ T-cells cultured alone. Data were gated first 
gated on CD8+ population and the percent of 7AAD-positive within the CD8+ cell population is 
shown in (A-D) as zebra plots. (E) Representative graphs showing percentage of dead CD8+ T-
cells. Experiments were repeated twice with similar results. 
 
 
Treatment of CRC cells with TSA enhances T-cell survival and activation similar to co- 
incubation with irradiated tumor cells. 
To investigate the impact of HDAC inhibition in tumor cells on T-cell survival, we 
measured T-cell death by 7AAD staining after 48hr co-incubation with tumor cells. 7AAD+ 
staining determined cell death of 8.96% of CD8+ T cells incubated alone (Fig. 3.6A). The 
frequency of dead CD8+ T cells increased to 24.8% following co-incubation with untreated 
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SW620 cells (Fig. 3.6B). Death of T-cells following interaction with tumor cells has been 
reported by others, and is thought to be caused by tumor expressed PDL1, FasL and/or activation 
induced cell death (AICD) (Zaks, Chappell et al. 1999, Chiou, Sheu et al. 2005, Prado-Garcia, 
Romero-Garcia et al. 2012). Incubation of T-cells with SW620 cells, that had been treated with 
TSA for 48hr, reduced the percentage of dead T cells to 17.6% (Fig. 3.6D) similar to incubation 
with irradiated tumor cells (16.6%). A reduction in T-cell death (18%) was also observed when 
T-cells were co-incubated with TSA-treated HCT116 cells as compared to untreated tumor cells 
(26%) (Fig. 3.6E). These data indicate that HDAC inhibition by TSA treatment of tumor cells 
increases the survival of CD8+ T cells following co-incubation with tumor cells. CD25 and 
CD69 are surface markers expressed on activated T cells (Zola 2000). Data from our lab supports 
the hypothesis that changes in the expression of tumor-expressed 41BBL and OX40L contribute 
to increased killing of irradiated tumor cells by CTLs (submitted manuscript). We have also 
observed increased expression of CD25 and CD69 on T cells following co- incubation with 
irradiated tumor cells compared to non-irradiated tumor cells. Lastly, we have observed 
increased viability of T cells cultured with irradiated tumor cells. We next determined if tumor 
cells treated with HDACi induced similar changes in T cell activation. Non-treated, irradiated or 
TSA treated tumor cells were co-cultured with CD8+ T cells, and after 48hr the expression of 
CD25 on T cells was measured by flow cytometry. We found that 29.5% of CD8+ T cells 
incubated with untreated tumor cells expressed CD25 (Fig. 3.7A), and this frequency was 
reduced compared to activation of T cells incubated alone (34.1%) (Fig. 3.7D). This reduction is 
not surprising as reduced activity and activation of T-cells following interaction with tumor cells 
has been described by others (Zaks, Chappell et al. 1999, Chiou, Sheu et al. 2005, Prado-Garcia, 
Romero-Garcia et al. 2012). The frequency of CD25+ within the CD8+T cell population 
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increased following co-incubation with either radiation-treated (Fig. 3.7B) or TSA-treated tumor 
cells to 35.3% (Fig. 3.7C). In fact, the frequency of activated T cells following co-incubation 
with TSA-treated cells was equal to T cells not co-incubated with tumor cells (34.1%). CD25 
expression in T-cells activated with PMA and ionomycin are shown as a positive control 
(Fig.3.7E). We evaluated a second CRC cell line and found that TSA-treated HCT116 cells also 
increased the frequency of CD8+CD25+ cells to 41%, as compared to the frequency activated in 
the presence of untreated HCT116 cells (36.6%) (Fig. 3.7F). Irradiated tumor cells also increased 
CD25+ expression to 36.4% and the dynamics of T-cell activated were similar in repeat 
experiments. We observed a similar increase in the frequency of CD69+ T cells following 
co- incubated with TSA-treated or irradiated tumor cells (data not shown). These data suggest 
that T cells exposed to TSA treated tumor cells have improved activation. As a component of 
the IL-2 receptor, CD25 it has been linked to increased survival in studies by others and thus 
could be a contributor to the increased survival we observe following TSA treatment (Fig. 3.6). 
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Figure 3.7 TSA-treated CRC tumor cells induce enhanced activation of CD8+ T-cells.  
 
SW620 cells were either (A) untreated, (B) irradiated or incubated with (C) 250uM TSA for 48hr 
or as previously described. Tumor cells were subsequently co-cultured with human CEA-specific 
CD8+T-cells for 48hr and the frequency of CD8+CD25+ T-cells was measured by 
flowcytometry. T-cell activation was also measured in (D) CD8+ T-cells cultured alone or (E) 
activated with PMA and ionomycin (P/I) for 24h. Data were gated first gated on CD8+ 
population and the percent of CD25+ cells within the CD8+ cell population is shown in (A-E) as 
histogram plots. (F) a summary graph of results showing percentage of CD8+ T-cells expressing 
CD25 in both SW620 and HCT116 cells. Experiments were repeated twice with similar results. 
 
76 
3.5 DISCUSSION: 
 Modulation of costimulatory molecules such as OX40L and 41BBL appear to be 
particularly important for maintaining effective immune responses against self-antigens 
presented by tumor cells. Here, we report that costimulatory molecule promoter histones can 
be acetylated in colorectal tumors in response to sub-lethal radiation (Fig. 3.5A). Most studies 
of radiation- induced gene expression have used large cytotoxic doses of radiation, and 
mechanisms of altered gene expression are much less explored in cells receiving low or sub-
lethal doses of radiation. Results of this study suggest that radiation therapy may be useful to 
specifically modulate gene expression within tumor targets. This mechanism would be useful 
against radioresistant cancer cells, and could occur even in the absence of immunogenic cell 
death (cell death that invokes enhanced antigen processing and presentation) (Tesniere, 
Panaretakis et al. 2008). Full understanding of specific mechanisms of immunogenic modulation 
(altered expression of immune relevant genes) (Hodge, Garnett et al. 2013) of irradiated tumor 
cells will be required to determine how to best utilize radiation as a “tool” to enhance cancer 
immunotherapy approaches. Dramatic changes in DNA methylation are common in cancer, and 
manifest primarily as global DNA hypomethylation, paralleled by local hypermethylation at gene 
promoters resulting in loss of gene expression (Feinberg and Vogelstein 1983, Rhee, Bachman et 
al. 2002). Tumor cells down-regulate the expression of many genes needed for induction of 
effective anti-tumor immune activity (Zamai, Rana et al. 1994, French and Tschopp 2002, 
Bubenik 2003, Slavin-Chiorini, Catalfamo et al. 2004), and DNA methylation may be one 
mechanism employed to accomplish this. Our studies reveal that inhibition of DNMT in 
tumor cells using 5-Aza-dC could induce mRNA expression of both OX40L and 41BBL on two 
different CRC cell lines (Fig. 3.1 & 3.2). Although a greater than 5-fold induction of mRNA was 
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detected in SW620 cells treated with 5-Aza-dC, we did not observe a robust increase in protein 
expression upon 5-Aza-dC treatment of these cells (Fig. 3.3). These discordant results could 
simply be a result of the time of evaluation post-treatment. 41BBL mRNA was maximally 
increased 72hr post-treatment with 5-Aza-dC, while protein expression was evaluated after 24h 
of treatment to keep cell death low at time of evaluation. Current studies are underway to 
determine if 5-Aza-dC can indeed upregulate protein expression at later times post-treatment. 
HDAC inhibition has been shown to be involved in modulating the expression of TNF 
family members (Sutheesophon, Nishimura et al. 2005, Earel, VanOosten et al. 2006). In this 
study we extended analysis to other TNF family members and found that both 41BBL and 
OX40L expression could also be modulated by inhibition of HDACs. We found that the 
expression of both OX40L and 41BBL was increased on the surface of tumor cells treated with 
TSA for 24hr (Fig. 3.3) or 48hr (Fig. 3.4). Interestingly, the impact of HDAC inhibition by TSA 
on 41BBL protein expression was much more robust than changes observed in the expression of 
OX40L protein following TSA treatment. Studies are currently underway to evaluate changes in 
histone acetylation at the OX40L promoter to determine how acetylation is impacted by TSA 
inhibition of HDACs. We also observed increased expression of co-stimulatory proteins as long 
as four days after TSA-treatment and irradiation. While many of the cellular stress response 
genes are acute response genes whose expression is altered transiently, other genes remain 
altered for prolonged periods of time (Chen, Quintans et al. 1995, Woloschak and Paunesku 
1997, Fornace, Amundson et al. 2002). As such, altered gene expression following radiation 
treatment that is sustained is not unexpected. 
The TNF family includes numerous costimulatory molecules known to play an important 
role in CD8+ T cell activation and survival. We found that inhibition of HDACs in tumor cells 
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resulted in enhanced T-cell survival (Fig. 3.6) and activation (Fig. 3.7). To our knowledge 
this is the first study to explore the impact of radiation-induced epigenetic changes in tumor cells 
on the quality of anti-tumor CTLs. We are currently investigating if, by promoting T-cell 
survival and activation, the altered expression of these specific genes by HDACi enhances the 
tumor cells’ susceptibility to T-cell-mediated immune attack in a manner similar to observations 
in irradiated tumor cells (submitted manuscript). Future studies seek to more fully investigate if 
increase signaling through CD25 is directly responsible for the increased survival of T-cells by 
evaluating T cells after shorter periods of co-incubation as well as investing intracellular 
regulators of T-cell apoptosis. 
HDACs enzymes reverse the activity of HATs by removing acetyl group and thus 
suppressing gene transcription. In several tumors, the expression of HATs is down-regulated, 
whereas HDACs is upregulated (Ropero and Esteller 2007, Sharma, Groselj et al. 2013). As 
previously mentioned, alteration of HAT and HDAC activity has been observed in tumor cell 
lines. HDACi induce a potent anticancer response by inhibiting HDACs (Redner, Wang et al. 
1999, Saunders, Dicker et al. 1999). HDACi have various biological effects, such as inhibition of 
cell cycle at G1/G2 phase, induction of differentiation and apoptosis of tumor cells (Rajgolikar, 
Chan et al. 1998, Kosugi, Towatari et al. 1999, Yoshida and Horinouchi 1999) 
 Our results reveal that radiation treatment changes the epigenetic landscape of the 
41BBL gene via an increase in histone acetylation, displaying a marked increase in H3 
acetylation at this specific promoter, as compared to our positive control of cells treated with the 
HDACi, TSA. We also observed that TSA induced robust 41BBL mRNA changes at earlier 
times of treatment (8h and 24h) while radiation-induced changes took longer and were greatest at 
later times of treatment (48h and 72h). These data, in combination with increase promoter 
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acetylation, suggest that radiation mediated effects take longer to modulate histone acetylation 
events than direct modulators such as TSA. This could be related to differences in modulation of 
HATs versus HDAC inhibitors. Current lab efforts are pursuing the mechanism for these 
epigenetic changes in primary carcinoma cells; specifically, does IR treatment change the 
activity of HATs, HDACs or both? If HDACs are involved, specific HDAC inhibitors will be 
utilized to identify which HDACs suppression(s) are vital for the upregulation of 41BBL 
expression. Also, how long can these epigenetic changes be maintained to promote increased 
effector T-cell function? Finally, we note that expression of OX40L and 41BBL varied with 
different concentrations of drug exposure. Our focus here is to describe a novel gene regulatory 
mechanism by epigenetic modification in response to irradiation. However, the application of 
clinically relevant doses of TSA and 5-Aza-dC, which might be combined with radiation, will 
also require a further investigation in a broad range of tumor cells. The current study was meant 
to enhance our ability to design cancer immunotherapy (CIT) approaches in combination with 
RT. A better understanding of how IR modulates the expression of 41BBL and OX40L will 
allow improvement in our ability to use RT to specifically enhance CTL killing. Epigenetic 
mechanisms of gene expression could be an alternative therapeutic approach to enhancing these 
important T-cell signals. This approach is particularly relevant given the toxicities associated 
with using agonistic antibodies to 41BB and anti-OX40 antibodies in the clinic (Garber 2011, 
Weinberg, Morris et al. 2011). Alternate ways of triggering these signal pathways would be 
widely applicable in current CIT approaches. Furthermore, if radiation is shown to have a 
profound and consistent effect on immune stimulatory gene expression, this would provide 
support for using IR in conjunction with CIT strategies to specifically enhance such signals to T-
cells arriving at tumor sites and optimize anti-tumor CTL responses. 
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4 The impact of radiation directly on TREG viability and phenotype and indirectly via 
tumor modulation 
4.1 ABSTRACT 
CD4+CD25+ T regulatory (TREG) cells are critical in maintaining self-tolerance to 
prevent autoimmune disease. On the other hand, TREG infiltration into tumors is undesirable as it 
inhibits endogenous cytotoxic antitumor immune responses, thereby boosting cancer escape from 
immune-surveillance (Curiel 2007). As a result, TREGS hinder the success of cancer 
immunotherapies in patients. This preliminary and exploratory study was designed to investigate 
the effects of immunogenic modulation of tumor cells by sub-lethal irradiation on TREG 
frequency and viability. CD4+CD25+FoxP3+ TREGS were purified from human PBMC 
samples. TREGS were co-cultured with human colorectal cancer cells and exposed to radiation 
together and separately. We found that irradiated human tumor cells do not robustly upregulate 
expression of TREG stimulating/promoting molecules.  In vivo, we found that local RT to tumor-
bearing mice resulted in reduced frequencies of TREG cells within the tumor.  In vitro, TREGS were 
less sensitive to cytotoxicity from IR as compared to CD4+ non- TREGS. Additionally, no 
significant difference was observed in TREG vs non- TREG viability after co-culture with irradiated 
tumor cells.  Interestingly, we found that IR modulated the phenotype of TREGS and reduced 
expression of TREG associated markers including Fox-P3. Importantly, the loss of FOXP3-
mediated suppressive functions may be linked to increased antitumor immune response. Overall, 
our findings suggest that sub-lethal doses of IR may reduce TREG detection within tumor tissues 
by altering their phenotype, and further, that it may reduce TREG mediated activities by reducing 
expression of genes required for their suppressive function.   
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4.2 INTRODUCTION 
   TREGS comprise 1-3% of total peripheral CD4+ T cells in human and 5-10% of mouse 
splenocytes. Regulatory T cells express high levels of CD25 (interleukin-2 receptor alpha chain) 
and forkhead box P3 (FOXP3); FOXP3 is recognized as a specific marker of TREGS   and it 
controls transcription of several genes responsible for the suppressive function of TREGS 
(Baecher-Allan, Brown et al. 2001, Brunkow, Jeffery et al. 2001).  TREGS are important cells of 
the immune system that inhibit and control unwanted immune responses against self-antigens, 
thus preventing the development of autoimmune diseases. Tumor cells secrete different 
chemokines such as CCL2, CCL-17 and CCL-22 which enhance trafficking of natural and 
induced TREGS (n/i TREGS) from peripheral circulation to tumor site (Gobert, Treilleux et al. 2009) 
(Facciabene, Motz et al. 2012). Recruited TREGS suppress the effector function of cytotoxic T 
cells present within the tumor by several mechanisms(Curiel 2007). In addition, transforming 
growth factor beta (TGF-β), released by tumor cells, increases expansion of preexisting TREGS 
within tumor (Yamagiwa, Gray et al. 2001, Ghiringhelli, Puig et al. 2005). Apart from 
recruitment and expansion of TREGS by tumor cells, naïve CD4+, memory CD4+ cells can be 
converted to TREGS in the presence of IL-10, TGFβ, and programmed death ligand-1 (PD-L1) 
(Puccetti and Grohmann 2007, Zhou, Zhou et al. 2009, Pothoven, Kheradmand et al. 2010).  
 Increased number of TREGS has been found in several different cancers; Woo and 
colleagues have reported increased number of intra-tumoral TREGS in lung and ovarian cancers 
(Clarke, Betts et al. 2006, Wolf, Rumpold et al. 2006). In report by Ling and colleagues, both 
intra-tumor and systemic accumulation of TREGS has been reported in colorectal cancer patients. 
In addition, the proportion of TREGS in peripheral blood of CRC patients was four times higher 
than the control. Furthermore, an increased frequency of TREGS was reported within tumor (19.2) 
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than the control (normal colon tissue, 9%) (Ling, Pratap et al. 2007). Infiltration of TREGS in gut 
under normal condition is desired, as it is a tolerogenic organ, however increased accumulation 
of TREGS in tumor tissue can inhibit effective tumor control by CD8+ T cells. Therefore, intra-
tumoral infiltration of TREGS is a major obstacle to success of current cancer immunotherapies.  
    We previously reported that sub-lethal doses of radiation modulated tumors making 
them more immunogenic for CD8+ effector T cells. Surprisingly, relatively few (and 
contradictory data) exist in the literature regarding effect of irradiation on TREGS directly, or the 
impact of irradiated tumors on TREGS. This is an important question because the cytolytic activity 
of activated CD8+ effector cells can be directly inhibited by the presence of regulatory T cells.    
It is unclear if immunogenic modulation of tumors by sub-lethal irradiation can influence TREG 
number and function. In addition, there is little known about the effect of radiation on human 
TREGS phenotype. The present study was designed to begin exploring the hypothesis that 
irradiated tumor cells undergo immunogenic modulation that decreases TREGS number and 
activity.  
4.3 MATERIALS AND METHODS 
 
Cell lines: Human colorectal carcinoma cell lines HCT116 were obtained from the 
laboratory of tumor immunology and biology, LTIB, NCI, NIH. SW620, Colo205 and human 
breast carcinoma cells lines MDA231 and MDA468 were purchased from ATCC cells. All cells 
were cultured as recommended by ATCC and tested periodically to ensure absence of 
Mycoplasma. Cells were incubated at 37°C incubator with 5% CO2.  
Irradiation: A RS-2000 biological X-ray irradiator (Rad source technology, Suwanee, 
GA) was used to irradiate tumor cells. Cells were irradiated at a dose rate of 2Gy/min at voltage 
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and current of 160kV and 25mA, respectively. Cells were maintained in suspension and kept on 
ice during irradiation. Immediately after irradiation, cells were centrifuged and cells were plated 
in tissue culture plates in fresh media. 
 
Generation and culture of TREGS: PBMCs from HLA-A2+ donors were purchased from 
Hemacare (Van Nuys, CA) for the generation of TREGS. Peripheral blood mononuclear cells were 
separated by density gradient centrifugation using Ficoll-Hypaque. Tregs were purified using the 
Miltenyi Biotec’s CD4+CD25+ regulatory T cells isolation kit. The freshly isolated cells 
cultured in a medium containing 1000IU/ml of IL-2, and activated with CD3 and CD28 beads for 
14 days (Hoffmann, Eder et al. 2004, Battaglia, Di Schino et al. 2005). Likewise CD4+ T cells 
were cultured under same condition. The purity of TREGS was determined by staining for CD4, 
CD25 and FOXP3 markers using Human regulatory T cells staining kit (ebioscience) by flow 
cytometry. To determine if changes are specific for TREGS, non- TREGS (CD4+ T cells) were 
cultured under same conditions and evaluated.  
 
RNA isolation: At 24 or 48hr post-IR, mRNA was extracted from tumor cells using 
RNeasy mini kit (Qiagen Inc. Valencia, CA) according to manufacturer’s instructions.  Purified 
RNA was DNase-treated by Rnase-free DNase (Qiagen Inc. Valencia, CA) following 
manufacturer’s instructions. 
 
Quantitative real time PCR for CCL22 and TGFB: Expression of CCL22 and TGF-β 
was mRNA was determined using real time qRT-PCR. cDNA was synthesized using 500ng of 
mRNA. Amplification of cDNA was done using DyNaAmo cDNA synthesis kit (Finnzymes. 
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Vantaa, Finland). Quantitative RT-PCR was conducted using sybr green.  PCR thermal cycling 
condition was 50°C for 2min, 95°C for 5min, 40 cycles of 95°C for 30sec and 50°C for 35sec in 
a total volume of 20 μl/reaction. Data were collected using a 7500 Real Time PCR System. All 
samples were run in duplicate. The expression level of each gene was compared between 
irradiated and non-irradiated samples 24 or 48hr post-IR.  Hypoxanthine 
phosphoribosyltransferase (HPRT) was used as an endogenous house-keeping control gene and 
samples were normalized to expression of this gene, which was unchanged by radiation.  Data 
were analyzed using the comparative ΔΔCt method. 
 
Flow cytometry: Cells were stained with primary labeled mAb PDL1-PE from BD 
biosciences (San Diego, CA) and Human regulatory T cells staining kit (ebioscience).  Surface 
staining was done in cell staining buffer for 30min on ice. Annexin-V-PE and 7AAD dye were 
purchased from BD biosciences (San Diego, CA) and used according to manufacturers 
instructions to measure cell death. Flow cytometry data were acquired on BD Fortessa and 
analyzed with FlowJo software (TreeStar, version 9.6).  The live cells population was gated on 
the FSC and SSC scatter plots for analysis of surface proteins. Samples were stained with the 
appropriate isotype control antibodies and gates were set to less than 5% in all isotype control 
samples.  
 
Statistical Analysis: For graphed flow cytometry data, the mean of three independent 
experiments was calculated and an un-paired one-tailed student T-test and one-way analysis of 
variance (ANOVA) were performed using Graph pad by Prism.  
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4.4 RESULTS 
Radiation therapy decreases TREG frequencies within tumors in vivo 
MC38 murine colon carcinoma cells were implanted s.c. into C57BL/6 mice. Local RT 
(8-10Gy) was given to the tumors 15 days after implant. The percentage of TREGS and CD4+ T 
cells was determined by flow-cytometry. We found that TREG numbers were reduced within 
tumors after 8Gy radiation as compared to CD4+ non- TREGS (Fig 4.1A). Moreover, the 
frequencies of both TREGS and CD4+ non-TREGS did not change after treatment in the spleen (data 
not shown).  We also evaluated changes in intratumoral TREG numbers using fluorescent 
immunohistochemical approaches and observed a reduction in FoxP3+ cells on tumors treated 
with 10Gy radiation (Fig 4.1B).  To determine if this was unique to the murine tumor cell line we 
selected we performed a similar analysis of a second murine tumor cell line, 4T1.  4T1 cells are 
derived from a murine mammary tumor cell line as thus also represent a different type of cancer.  
Tumor cells were implanted s.c. and treated with 8Gy between day 10 and 15 (to allow for the 
treatment of tumors of relatively equal size).  Forty-eight hours after RT tumors were excised, 
sectioned and stained by immunofluorescence for Fox-P3 cells.  RT resulted in a significant and 
robust reduction in the presence of FoxP3 cells present in the tumor tissue (Fig 4.2).  These data 
suggest that the doses of radiation used in this study are able to reduce the frequency of TREGS in 
vivo and that this is observable in more than one murine tumor type.   
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Figure 4.1. The number of TREG cells following vivo RT of murine colorectal tumors.  
 
A. Percentage of CD4+ T cells and CD4+CD25+Foxp3+ cells from in vivo tumor samples 
determined by flow cytometry. Female C57BL/6 mice were s.c implanted with 5 x 105 MC38 
colorectal tumor cells. After 10-15 days tumors (200-250mm3) were irradiated with 0 or 8 Gy. 
48h later mice were euthanized and tumors excised. Tissue was homogenized into a single cell 
suspension, red blood cells lysed and samples stained for overall CD4+ cell numbers and 
CD4+CD25hiFoxp3+ TREG cell numbers. B. The number of FoxP3+ cells per mm
2 in tumor 
tissue. Irradiated (10 Gy) and non-irradiated (0 Gy) tumor tissue was excised 24-hrs post-IR. 
Tissue was fixed, sliced, and immunofluorescence performed to detect FoxP3 expression. Each 
dot represents the average FoxP3+ cells in individually treated mouse tumor (4-6 view regions 
were counted per tumor). Unpaired t Test (one-tailed) was performed to assess statistical 
significance; p=0.0911.  
 
 
Figure 4.2. The number of FoxP3+ cells following vivo RT of murine breast tumors.  
 
Irradiated (8 Gy) and non-irradiated (0 Gy) female Balb/c mice implanted s.c. with 8 x 105 4T1 
breast cells were irradiated 10-15 day post-implant.  48-hrs post treatment tumor tissue was 
excised, fixed, sliced, and immunofluorescence performed to detect FoxP3 expression. A. Each 
dot represents the average FoxP3+ cells in individually treated mouse tumor (4-6 view regions 
were counted per tumor).  An unpaired t Test (one-tailed) was performed to assess statistical 
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significance; p=0.0082. B. A representative view region from an irradiated and non-irradiated 
mouse. Red - FoxP3; Blue - nucleus. 
 
 
Irradiation increases TGF-β mRNA but does not change other TREG promoting 
molecules  
    We previous reported that IR could modulate tumor cells to express surface proteins 
that were stimulatory to CD8+ effector T cells (Chapter 1).  On the contrary, both OX-40L and 
4-1BBL have been reported to reduce TREG function.  This supports the notion that IR 
modulation of tumors favors promotion of effector T cell activity instead of TREG activities. This 
is on contrast to speculation by many who predict that RT will promote TREG accumulation based 
on the finding of a single study using high dose RT. Thus it is critical to investigate if radiation is 
capable of modulating important signals to TREGS.  This could occur through change in the 
expression of TREG promoting molecules that that could alter recruitment or maintenance of 
TREGS in tumor cells following RT.  To determine whether irradiated tumor cells secrete or 
express molecules that could alter TREG numbers, we evaluated expression of TREG promoting 
cytokines, chemokines and ligands from irradiated tumors.  We reasoned that reduced expression 
of such proteins following IR could be responsible for the reduced presences of TREGS in 
irradiated tumors. CCL22 is a chemokine, which recruits TREGS. CCL22 mRNA was measured in 
HCT116 cells 8-48h-post irradiation, and we observed no significant change in mRNA 
expression over the time (Fig 4.3A). Next we examined if surface expression of PDL1, which 
causes conversion of CD4 cells into TREGS, was reduced following irradiation of tumor cells. 
Surface expression was measured by flow cytometry following 10Gy tumor radiation (Fig 4.3B). 
The expression was not changed in irradiated cells versus untreated tumor cells 48hr post IR.   In 
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contrast, a breast cancer cell line MDA231 a, expressed very high basal level expression of 
PDL1 and was used as a positive control since no change was observable in the CRC cell lines. 
Next, we examined TGF-β transcript level as this cytokine is known to enhance proliferation of 
TREGS. TGF-β was significantly increased in both HCT116 and SW620 at 48hr post-IR (Fig 
4.3C-D).  Further, increased expression could be detected as early at 24hr post-IR in SW620 
cells (Fig 4.3D). Curiously, though TGF-β mRNA expression was increased in irradiated tumors, 
we did not detect an increase in the protein in the supernatants of irradiated tumor cells (data not 
shown). The biology of active TGF-β from its latent form is a regulated process (ref) and our 
findings suggest that the message could be subject to post-translational regulation that inhibits 
production of the functioning cytokine.  Overall, these data suggest that   irradiated tumor cells 
do not globally reduce the production of pro- TREG factors.  Though there are other TREG 
promoting products it seems unlikely that modulation of tumors by radiation is reducing TREG 
numbers by reducing the expression of TREG promoting genes.  
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Figure 4.3. Radiation induced changes in TREG promoting factors in human tumor cells.  
 
A. HCT116 and SW620 cells were irradiated with 10Gy, mRNA was harvested, and the 
expression of CCL22 was evaluated 8, 24 and 48h post-IR. B.  HCT116 and Colo205 CRC cells 
were treated with 10Gy IR and surface expression of PD-L1 was evaluated 48 h later by flow 
cytometry.  MDA231 cell were used as a positive control for detection.  C. TGF-β mRNA 
expression was evaluated in irradiated HCT116 and SW620 cells 8, 24 and 48h post-IR.     
 
 
Irradiated tumor cells do not promote death of TREG, and CD4+ TREGS are not more 
sensitive to radiation than CD4+ non- TREG-cells 
  As we did not observe a robust reduction in TREG promoting molecules in irradiated 
tumor cells we next evaluated if irradiated tumor cells had an impact on TREG viability. To test 
the influence of irradiated tumor on newly recruited TREGS from periphery in tumor 
microenvironment, tumor cells were irradiated alone and after 48hr TREGS were added (Fig 
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4.4A). The number of dead TREG was measured by Annexin-V and 7AAD staining 24hr post co-
culture. Very few dead TREGS cells were detected in TREGS incubated with both irradiated and 
non-irradiated tumor cells (less than 20% dead cells). A similar trend was seen in CD4+ non- 
TREG cells. Next, to mimic in vivo conditions, where both TREG and tumor cells receive 
radiation simultaneously, we irradiated TREGS and tumor cells during co-culture and evaluated 
TREG viability 48h later. We observed an increase in the number of dead cells in both the TREG 
and CD4+ non-TREGs cultures after 5Gy of RT however the difference was not statically 
significant (Fig 4.4B). Collectively, we saw no difference in the viability of TREGS as compared to 
CD4+ non- TREGS   following irradiation in the presence of tumor cells or when added to cultures 
of previously irradiated tumor cells. We next tested the impact of radiation directly on TREG and 
non-TREG cell viability directly as others contradicting studies have reported that TREGS are both 
more and less sensitive to RT than non- TREGS (ref). For these experiments TREGS and CD4 non 
TREG cells were irradiated alone and cultured for 48 (Fig 4.4C) or 72h (Fig 4.4D).  We detected 
significantly more dead CD4non-TREG cells after direct radiation compared to the increase in 
dead TREG cells after radiation treatment. This suggests that TREG were more resistant to radiation 
than the non-TREG cells. To verify our results by another method, we measured viability by 
trypan blue. Again, CD4 T cells were more sensitive to radiation than TREGS (data not shown). 
The experiment was repeated three times with similar results.  These data suggest that human 
CD4+ TREGS are more radioresistant than CD4+ non- TREGS at lower doses such as 5Gy.  
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Figure 4.4 The effects of irradiated tumor cells and direct RT on TREG and non-TREG cell 
viability. 
 
A. HCT116 cells were irradiated with different doses of irradiation (2.5 or 5Gy). After 24hr, 
TREGS or non TREGS were added  to the culture of irradiated tumor cells. After 72-hrs TREGS/ non 
TREGS were harvested, stained with Annexin-V and 7-AAD, and analyzed by flow cytometry to 
assess cell viability. B. HCT116 tumor cells and TREGS/ non TREGS were irradiated (2.5 and 5 
Gy), co-cultured for 48-hrs and cell viability measured by flow cytometry. C. TREGS and CD4+ 
non-TREGS were irradiated alone (2.5 and 5 Gy) and cell viability measured 48-hrs post-IR. D. 
The viability of TREGS/ non TREGS was measured by Trypan blue staining 72-hrs post-IR after 
irradiation alone.  
 
Radiation directly modulates the phenotype of TREG cells. 
    TREGS express CD4, high levels of CD25 on their surface and FOXP3 intracellularly. 
FOXP3 is an important transcription factor that regulates TREGS suppressive function (Fontenot, 
Gavin et al. 2003, Hori, Nomura et al. 2003). Our results suggest that TREGS number is not 
significantly affected by tumor irradiation. Next, we examined if radiation altered phenotype of 
TREGS reasoning that if the expression of TREGS markers was reduced post-IR this could account 
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for the decreased frequencies of TREGS within irradiated tumor cells (Fig 4.1) CD4+CD25+ cells 
were isolated from human peripheral blood mononuclear cells (PBMC) and TREGS were 
irradiated in vitro and evaluated for expression of TREG specific markers. We found that less cells 
stained positive for both CD4 and CD25 after exposure to IR (Fig 4.5A). We also found that 
within the CD4+ population the frequency of cells that expressed high levels of CD25 was 
reduced (Fig 4.5A) which could explain why there is less change observed in CD4+ cells 
following in vivo RT of tumors as compared to the change in CD4+CD25hi cells post-IR (Fig 
4.1).  We next evaluated how the expression of FOXP3 was affected by radiation treatment of 
Treg cells.  We found Foxp3 expression to be significantly reduced after 10Gy of radiation (48 
or 72hr) (Fig 4.5B). Thus, it seems plausible that the reduction in TREGS number (in vivo) is due 
to loss of TREG specific markers in TREGS after RT.  
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Figure 4.5.  Radiation directly modulates the phenotype of T-REG cells.  
 
A. Purified human CD4+CD25+ regulatory T cells were exposed to single dose of radiation 
with10Gy.  After 48, TREGS were stained for expression of CD4 and CD25. B. The expression of 
and Foxp3 was evaluated within the TREG population Expression. Experiments were repeated 
three times with similar results. 
 
4.5 DISCUSSION: 
   Radiotherapy is integral part of cancer treatment. Traditionally, RT is thought to 
mediate its effect by direct killing of tumor cells. Interestingly, recent research indicates that 
radiation also affects systemic antitumor immune response (Formenti and Demaria 2013). There 
are many conflicting reports on the impact of radiation on CD4+ regulatory T cells (TREGS), 
which play a major role in immune tolerance by suppressing autoreactive T cells. In cancer 
patients, however, TREGS inhibit the generation of successful antitumor immune response and 
increased infiltration of adaptive TREG is often detected within the tumor microenvironment 
(Woo, Chu et al. 2001). Therefore, defining strategies that reduce TREG number and function in 
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cancer patients is important for augmenting the success of cancer immunotherapies. In this study 
we focused on both direct and indirect (via irradiation of tumor) effects of radiation on TREG cell 
biology and viability.   
 
 Human TREGS were treated under three different conditions. First, tumor cells were 
irradiated and TREGS were subsequently added to elucidate the effect of locally irradiated tumor 
on newly recruited TREGS to tumor site. There was no difference in viability of TREGS after 
coculturing TREGS with irradiated tumor vs non-treated (Fig 4.4). Second, tumor and TREGS were 
irradiated simultaneously during cocultured together to mimic what might occur in vivo if TREGS 
were already present within the tumor. There was a dose dependent increase in TREG cell death as 
well as death of CD4+ non TREGS suggesting that there was no specific enhancement of TREG cell 
death in the presence of tumor cells. Lastly, TREGS and non- TREGS were irradiated alone to 
compare their individual sensitivity to radiation. We observed that TREGS are more resistant to 
radiation compared to non- TREGS. Overall, our data suggest that radiation of tumor cells does not 
alter the viability of TREGS but that TREGS are less sensitive to radiation-induced toxicity 
compared to CD4 cells. This finding is in contrast to a report by Cao et al that apoptosis was 
higher in TREGS than effector T cells. This difference could be a result of the different methods of 
isolation of human TREGS used or method for detection for cell death. 
Because direct toxicity to TREGS did not seem to account for reduced number of TREGS in 
irradiated tumors we considered if tumor cells could be modulated in such a way that makes 
them less likely to recruit or induce TREGS. Tumor cells secrete different chemokines such as  
CCL-22 which enhance trafficking of natural and induced TREGS (n/i TREGS) from peripheral 
circulation to tumor site (Gobert, Treilleux et al. 2009) (Facciabene, Motz et al. 2012). In 
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addition, transforming growth factor beta (TGF-β) released by tumor cells, increases expansion 
of preexisting TREGS within tumor (Yamagiwa, Gray et al. 2001, Ghiringhelli, Puig et al. 2005). 
Apart from recruitment and expansion of TREGS by tumor cells, naïve CD4, memory CD4 cells 
can be converted to TREGS in the presence of IL-10, TGFβ, and programmed death ligand-1 (PD-
L1) (Puccetti and Grohmann 2007, Zhou, Zhou et al. 2009, Pothoven, Kheradmand et al. 2010). 
Overall our results suggest that sub-lethal radiation of tumor cells does not change CCL22 and 
PDL1 (Fig 4.3). In contrast the expression of TGF-β mRNA was up regulated in both HCT 
(48hr) and SW620 cells after 10Gy. However, we saw a decrease in TGF-β protein in 
preliminary experiments (data not shown).  Future experiments will need to further assess if 
there is a true increase in functionally active TGF-β. Apart from tumor cells, there are many 
other cells present within the tumor microenvironment such as stromal cells, myeloid and DC 
cells also capable of secreting different factors, which could be responsible for the decreased 
frequency of TREGS. Overall, our data do not argue strongly for modulation of tumors by 
radiation subsequently reducing intratumoral TREGS. 
 
    Radiation has, however, been shown by us and others to modulate tumors directly 
making them more immunogenic and stimulatory for CD8+ effector T cells. This activity occurs 
in the absence of antigen presenting cells and is distinct from the immunogenic cell death (ICD) 
mechanism reported by others.  In this regard, investigations aimed at promoting ICD use high 
doses of radiation (24-30Gy) to induce some tumor cell death. Some, but not all, of these 
investigations have reported increased frequencies of TREG cells post-IR. In contrast, our current 
study utilizes lower dose of radiation (10Gy) and we found a reduction in TREG cells following 
RT of murine tumors (Fig 4.1). This loss appears to be specific for TREGS as there was no 
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reduction in CD4+ non TREG cells.  This finding is in line with reports using total body radiation 
(TBI), which demonstrate a reduction in TREG numbers. TBI also uses lower doses of radiation 
(2Gy or less).  However, as these studies were conducted in non-tumor bearing mice it was 
unclear what the effect of lower dose of radiation would be in tumor bearing mice. Because the 
tumor type evaluated could also play a role in whether RT promoted or inhibited TREGS we also 
evaluated mice implanted with a murine breast tumor (4T1).  This model was selected because 
several of the studies demonstrating increased Tregs (after 24-30Gy) utilized this tumor model 
system.  Again, we found a reduction in intratumoral TREG cells following 8Gy RT of murine 
tumors in vivo (Fig 4.2).  Our findings, suggest that dose is a major factor in the control of TREG 
cell frequencies within IR-treated tumors and that it can be effective in reducing TREG numbers in 
diverse tumor types.   
   Radiation did specifically induce death in TREGS as compared to non TREGS (Fig 4.1 and 
Fig 4.4), nor did irradiated tumor cells appear to modulate the expression of genes that would 
result in reduced frequencies of intratumoral TREGS (Fig 4.3). We next wanted to determine if 
radiation could perhaps be changing the phenotype of TREG cells. We observed that 10Gy 
radiation reduced the population of CD4+CD25hi cells in in vitro purified human TREGS (Fig 
4.5A).  We also observed that TREGS lost intracellular FoxP3 expression after 10Gy (Fig 4.5B).  
Similarly, Cao et al reported that RT decreased Foxp3 expression but the radiation dose used in 
their study was very high (30Gy). Thus, it could be possible that the decreased number of TREGS 
we observe in our in vivo model, may be due to losses in the expression of phenotypic markers 
of TREGS. Foxp3 is a transcription factor that controls transcription of several immunosuppressive 
genes such as IL-10, TGFB, and CTLA-4 that mediate the suppressive function of TREGS.  Thus, 
future studies will need to measure the expression of genes that are regulated by FOXP3 as well 
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as measure the suppressive activity of these TREGS post RT. Moreover, we also want to evaluate 
how FOXP3 expression is altered by radiation as HDACi with TSA has been reported to reduce 
FOXP3 expression.  This is of interest as I have seen TSA alter gene expression in tumor cells in 
a manner similar to the changes occurring following TSA treatment (Chapter 3).   
    Overall, results of this exploratory study have found that human TREGS are not more 
sensitive to radiation than non- TREGS at doses of radiation within the hypofractionated range 
used clinically.  Importantly, these doses of radiation do however reduce the frequency of TREGS 
present within the tumors of irradiated mice. This may be a consequence of radiations ability to 
alter the phenotype of TREG cells and could be responsible for reduced TREG function within 
tumors.  
 
 
 
 
 
5 CONCLUSION: 
 RT is an integral component of cancer treatment. The standard therapies in advanced stages 
of CRC include surgery, chemotherapy, targeted therapy, and radiation therapy (RT). In rectal 
cancer, RT is usually given either before or after surgery. In addition, radiation can be given in 
colorectal patient to reduce pain symptoms. Traditionally, RT was thought to be 
immunosuppressive; however, current studies suggest that RT can enhance antitumor immune 
responses. More recent reports demonstrate that sub-lethal doses of radiation can cause 
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immunogenic modulation of tumors that involves radiation-induced molecular alteration of 
tumor cells and make tumor cells sensitive to immune cell mediated killing (Hodge, Kwilas et al. 
2013).  This activity of radiation is separate from its ability to induce immunogenic cell death 
(ICD) and induction of activated antigen presenting cell and cross priming of T cells. Thus, fully 
defining the molecular mechanisms that allow IR to enhance anti-tumor immune responses will 
provide additional opportunities for enhancing cancer immunotherapies via combination 
strategies. 
Our previous studies demonstrate that sub-lethal doses of radiation alters gene expression 
within tumor cells, that make irradiated tumor cells more sensitive to CTL mediated killing 
compared to non-irradiated cells (Garnett, Palena et al. 2004). Another study from our lab 
reported that the enhanced killing was not dependent on death receptors (such as Fas) because 
human colorectal cells, which lack a functional Fas pathway (SW620), are still more sensitive to 
CTL mediated lysis after IR (Ifeadi and Garnett-Benson 2012) Moreover, the relative 
sensitivities to other death receptor pathways did not relate to the differential sensitivity to CTL 
killing. These studies suggest that alternate mechanisms could be responsible for enhanced 
killing.. T cell activation requires peptide bound on MHC molecules presented by antigen 
presenting cells (APC) to T cell receptor, in conjunction with appropriate co-stimulation to 
augment and amplify the immune response. Thus, in the second chapter we investigated the 
expression of costimulatory molecules such as OX40L, 41BBL, ICOSL and CD70, which are 
known to enhance effector activity of CTLs, on irradiated tumor cells. Both 41BBL and OX40L 
are required for perforin, granzyme, and IFNgamma production and thus promote T cell 
mediated killing. Single dose radiation (10Gy) significantly enhanced the surface expression of 
OX40L and 41BBL in panel of CRC cells (HCT116, SW620, WiDR).  All cells lines increased 
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expression of at least one of these two proteins except for the cell line Colo205. Transcript levels 
correlated well with the increase in protein expression. In contrast no change in other 
costimulatory molecules such as CD70 or ICOSL nor of the co-inhibitory molecule (PD-L1) was 
observed on the surface of colorectal tumor cells post irradiation. Furthermore, our study 
demonstrates that both OX40L and 41BBL are required for enhanced killing of irradiated tumor 
cells mediated by T cells as blocking of these molecules reversed CTL killing. Apart from 
killing, cell death was reduced and activation  (as measured by CD69 and IL-2 receptor 
expression) was increased in cytotoxic T cells following co-culture with irradiated tumor cells 
compared to T cells cultured with untreated cells. Thus, it is plausible that T cells survive better 
which would result in better productive interaction between T cells and tumor cells and 
subsequently results in enhanced killing. Based on our findings we can now add increased 
expression of effector T cell co-stimulatory molecules to the immunogenic changes induced in 
tumor cells surviving radiation (Fig 5.1).  
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 Figure 5.1 Immunogenic Modulation (IM) of Tumor Cells by IR.  
 
 *PD-L1 has been reported to be both increased, and decreased, by IR. Tumors have been 
reported to be modulated in several ways, which could directly enhance the function, activity or 
recruitment of CD8+ T cells, as well as the function of NK and dendritic cells.  Increased TAA 
could result in increased presentation on MHC-I to effector CTLs but could also make more 
antigen available for uptake by APCs. There have also been limited reports of modulation of 
tumors in a manner that could negatively impact CD8+ T-cell activities.  Note: IR-induced ICD 
mechanisms that enhance DC activities are not depicted in this figure.  Ag-antigen (Figure from 
Kumari et al, Future Oncology, in press) 
 
Overall, radiation appears to be overwhelming positive and in favor or enhanced effector 
T cells responses at the doses utilized in our studies (Fig 5.1).  These are important findings 
given the fact that there are many patients where T cells of known specificity for tumors already 
exist (or are even transferred in) but are not effectively attacking the tumor (Chakraborty, 
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Abrams et al. 2003). In these situations radiation is not needed to “prime” an initial T cell 
response to the TAA, via ICD, because large numbers of effector cells are already present. Local 
RT can be quite useful in this situation to greatly enhanced activity of T cells by providing these 
existing T cells with different or better signals from the irradiated tumor (Cao, Daniel et al. 2002, 
Lugade, Moran et al. 2005). Thus, it seems likely that T cells within the tumor which are primed 
but anergic could benefit from the increased co-stimulation.  
 
 Currently, the “holy grail” of radiation therapy from the CIT perspective is to find the 
mechanisms which induce the absocpal effect. The abscopal response describes the phenomenon 
of radiation delivered to a primary tumor inducing a response or regression of a distant non-
irradiated tumor. Unfortunately, abscopal responses are a rare unexplained phenomenon and the 
exact mechanisms remain unknown. Recent reports have achieved abscopal responses after 
combining radiation with immunotherapy (CTLA4 blockade) against melanoma and non- small 
lung carcinoma (Postow, Callahan et al. 2012, Golden, Demaria et al. 2013). Currently, various 
preclinical and clinical labs are investigating the underlying mechanism behind the abscopal 
effect so as to extend the effect to large number of patients and to achieve maximal benefit from 
combination of RT and CITs. Indeed, it seems likely that costimulatory molecules such as 
OX40L and 41BBL, changed after radiation could mediate such responses because these positive 
co-stimulators not only enhance local killing by CTLs but also enhance effector activity of 
CTLs, which are leaving the irradiated tumor. 
 
 In Chapter 3, we investigated the molecular mechanism by which radiation induced 
expression of co-stimulatory molecules. Previously several mechanisms have been reported for 
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RT-induced changes in gene expression in tumor cells.  Radiation causes DNA double strand 
break that activate ATM, which further activates its target genes such as NFkb and p53. NFkb is 
known to increase some immune relevant genes such as MHC-I, ICAM-1 and some 
inflammatory cytokines. In contrast, p53 alters the expression of genes, which are involved in 
cell cycle, apoptosis or DNA repair pathways. These pathways typically induce short duration 
changes, however we have observed that expression OX40L and 41BBL is sustained for up to 7 
days after single dose radiation. Others have found that these genes, as well as many other genes 
related to oncogenic pathways, could be controlled by epigenetic changes, which could mediate 
such long lasting changes in expression. For example, 41BBL expression was transcriptionally 
activated by HDAC inhibitors in leukemia cell lines (Vire, de Walque et al. 2009) and HDAC11 
was shown to play an essential role in regulating OX40L expression (Buglio, Khaskhely et al. 
2011). Importantly, radiation has been shown to inhibit the expression of HDAC1 and HDAC2 
(Han, Zhang et al. 2012). Epigenetic changes such as histone modifications and DNA 
methylation play important roles in regulating gene expression. We found that both HDAC and 
DNMT inhibitors enhanced expression of OX40L and 41BBL mRNA in HCT116 and SW620 
cells post irradiation. Surface expression of OX40L and 41BBL was also increased on tumor 
cells after 24hr treatment with HDACi (TSA) but not induced by DNMTi. We reasoned that 
DNMTi usually takes longer to induce gene expression, thus future experiments we will look at   
later times post treatment for the impact of DNMTi. In addition, HDACi (TSA) results in 
enhanced survival and activation of T cells, which are co-cultured with TSA, treated tumor cells. 
A finding very similar to the impact of radiation treated tumor cells on T cells.  We determined 
that radiation induced expression of 41BBL by increased histone H3 acetylation at the 41BBL 
promoter. To further determine if radiation was globally increasing histone acetylation at other 
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genes promoter we evaluated the histone acetylation level at the CIITA gene promoter. The 
acetylation level was similar between untreated and irradiated tumor cells. Thus our study 
suggests that radiation is   increasing histone acetylation specifically at the 41BBL promoter. 
These findings initiated a subsequent study by Cacan et al (Cacan IJO 2015) that demonstrated 
that radiation (5Gy) similarly increases histone acetylation at both the Fas and DR5 promoters in 
addition to the 4-1BBL promoter. This study also found less HDAC2, HDAC3, and DNMT1 
were bound to the promoter regions of both 4-1BBL and Fas, but not other genes following IR of 
human tumor cells (Cacan, Greer et al. 2015). Overall, these findings allow for expansion of the 
known pathway through which RT can modulate gene expression in surviving tumor cells (Fig 
5.2).  Interestingly, these data also suggest that the therapeutic use of epigenetic drugs in cancer 
may also be working through modulating these positive signals to T cells. In our future 
experiments we will determine how HDACs are being recruited to specific promoter sites 
following radiation, as well as determine how long these epigenetic changes can be sustained on 
tumor cells. 
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Figure 5.2  Diverse Mechanisms of Immunogenic Modulation (IM) Reported in Tumor 
Cells Surviving Radiation.   
 
*NFkB has been reported to be both inhibited and activated at lower radiation doses depending 
upon tissue and length of exposure.  (Figure from Kumari et al, Future Oncology, in press) 
There are many conflicting reports on the impact of radiation on CD4+ regulatory T cells 
(TREGS), which inhibit the generation of successful antitumor immune responses. In chapter 4, we 
began to explore the direct and indirect (via irradiation of tumor) effect of radiation on TREG 
biology and viability. Surprisingly we found that irradiated human tumor cells do not robustly 
alter expression of TREG stimulating/promoting molecules.  On the contrary, both OX-40L and 4-
105 
1BBL (shown to be modulated in Ch1) have been reported to reduce TREG function.  This 
supports the notion that IR modulation of tumors favors promotion of effector T cell activity 
instead of TREG activities.  In vivo, we found that local RT to tumor-bearing mice resulted in 
reduced frequency of TREG cells within the tumor and increased expression of both OX40L and 
41BBL could be detected in vivo (data not shown). The reduction in TREGS could have been the 
result of increased cell death of TREGS by IR directly, however, we found that human TREGS are 
actually less sensitive to cytotoxicity from IR in vitro as compared to CD4+ non- 
TREGS. Intriguingly, we found that IR modulated the phenotype of TREGS and reduced expression 
of TREG associated markers including the transcription factor FoxP3. Overall, our findings 
suggest that sub-lethal doses of IR may reduce TREG detection within tumor tissues by altering 
their phenotype and further that it may reduce TREG mediated activities by reducing expression of 
genes required for their suppressive function.  Future experiments will determine if expression of 
OX40L and 4-1BBL could contribute additional mechanisms of TREG inhibition within irradiated 
tumors, as well as if IR-mediated reduction in FoxP3 expression also reduces TREG suppressive 
function. 
 
    The main goal of cancer immunotherapy is to trigger the host’s own immune response 
against tumor cells. Immunotherapy approaches include checkpoint blockade antibodies, 
therapeutic vaccines, positive costimulatory agonist antibodies, ACT, and TLR agonists. Given 
the evidences that radiotherapy can do more than induce immunogenic death of tumor cells, but 
can also modulate the phenotype of tumor cells in way that can stimulate cytolytic immune cells 
(Figure 5.1), it is time to fully take advantage of all the immune stimulating actions of radiation. 
The success of the combination of immunotherapies and radiation depends on immunologic 
106 
phenotype of the tumor. Tumors have multiple immunoevasive and immunosuppressive 
strategies that can hinder the success of immune therapy. The first barrier is toleragenic dendritic 
cells which often accumulate within the tumor that suppress T cell priming and activation and in 
this scenario RT alone is not sufficient to activate T cells. Thus, in this condition, 
immunotherapies such as local administration of Toll-like receptor (TLR) agonist including 
TLR9 and TLR7 (TLR expressed on dendritic cells and recognize pathogen associated molecular 
patterns) are needed to activate or recover the function of DCs (Adams 2009). The second barrier 
is that tumors often express low MHC-1 and costimulatory molecules and escape from immune-
recognition. Thus, radiation can be used after TLR agonist to enhance the expression of 
costimulatory molecules (such as OX40L and 4IBBL as I have shown in this dissertation) on 
tumor cells which would transduce positive signals to CTLs and enhance their killing and also 
survival and activation of effector T cells (chapter 2). In addition, based on the work I have 
shown here, it now seems likely that these positive signals can also be induced by epigenetic 
drugs such as HDAC inhibitor (chapter 3). Thus, combination of HDAC inhibitor with 
immunotherapies are another area of potential combination in future cancer therapy. Finally, in 
some patients despite the presence of activated T cells within tumors, programmed death ligand 
(PD-L1) causes T cells exhaustion.  This protein is upregulated by colorectal tumors post 
irradiation (Dovedi, Adlard et al. 2014). So far it is unclear whether radiation induced positive 
signals can override the negative signal (PDL1) to a T cell but adding a checkpoint blocking 
antibody with radiation has been shown to enhance the generation of productive antitumor 
immune responses. Thus, combining an immunocheck point inhibitor (PDL1 or PD1 blockade) 
with radiation is required to overcome T cell inhibition. Overall, localized RT has emerged an 
adjuvant in combination with immunotherapies.  
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IM-induced phenotypic changes in tumor cells have been studied extensively (Fig 5.1).  
However, given the differential radio-sensitivities of immune cell subsets, it seems imperative to 
more fully elucidate the direct effects of radiation doses within the hypofractionated dose range 
on immune cell phenotype and function. Particularly given the changes we have observed within 
irradiated TREG cells.  It will also be important to determine which phenotypic changes occur 
most broadly in surviving tumor cells, and can thus be capitalized on across diverse human 
tumor types. Regarding the TME, how other cells besides tumor cells are modulated at these 
doses needs to be elucidated. Given our evidence that IM of some genes is occurring via 
epigenetic mechanisms, determining how long these changes are retained in tumor cells as well 
as what other immune relevant genes are regulated this way will be helpful for defining the 
therapeutic usefulness of RT-induced IM. It is perhaps most important to determine which 
changes occur in instances where abscopal responses are seen so that we can induce this type of 
response more consistently. Overall, such data will allow for determination of which CITs 
should routinely incorporate RT for its IM activities allowing for the rationale incorporation of 
RT into CIT approaches.   
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